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ABSTRACT
This dissertation focuses on the role of palmitoylation in regulating the sodium
hydrogen exchanger isoform 1 (NHE1) and associated cellular functions as well as how
various phosphorylation pathways alter NHE1 palmitoylation. Palmitoylation is the only
known reversible lipid modification, allowing for the dynamic regulation of palmitoylated
proteins not found with other lipid modifications. NHE1 regulates intracellular pH (pHi) by
exchanging an extracellular sodium for an intracellular hydrogen. Additionally, NHE1 is
involved in regulating cell volume, cytoskeletal organization, protein anchoring, cell
migration, and cell proliferation. NHE1 is highly regulated by protein interactions and
modifications including phosphorylation. To begin, the first study shows NHE1 is
palmitoylated in cells and rat tissues and can be inhibited by 2-bromopalmitate (2BP), a
global inhibitor of palmitoylation. Furthermore, inhibition of palmitoylation with 2BP
affects multiple NHE1 associated cell functions including pHi, stress fiber formation,
proliferation and migration.
Continuing to look NHE1 regulation, we used various agonists known to effect
NHE1 phosphorylation followed by examination of NHE1 palmitoylation. Serum,
lysophosphatidic acid (LPA) and phorbol 12-myristate (PMA) treatments all increased
NHE1 palmitoylation while insulin decreased NHE1 palmitoylation. Multiple studies have
shown that palmitoylation and phosphorylation within the same protein can impact each
other in various ways and thereby work together to regulate protein function. As NHE1 is
highly phosphorylated, we also utilized specific kinase inhibitors and measured the effect

1

on NHE1 palmitoylation. We found inhibition of PI3K, AKT, Rsk, and ROCK increased NHE1
palmitoylation while MEK inhibition decreased NHE1 palmitoylation. Together these
studies establish a role for palmitoylation in the regulation of NHE1 activity and associated
cellular functions and demonstrate palmitoylation and phosphorylation events may work
in a coordinated manner to regulate NHE1.

CHAPTER I
BACKGROUND
Post-Translational Modifications

Proteins are the basis of cellular and physiological functions and their chemical
and physical properties regulate activity and function within the cell1,2. Cellular proteins
are regulated by a diverse range of chemical modifications on their amino acid side chains.
These various modifying groups can affect charge, hydrophobicity, and other aspects of
protein chemistry, resulting in marked changes in the behavior of protein molecules and
hence in the control of physiological mechanisms3. Protein posttranslational
modifications (PTMs) alter the physiological properties of proteins to change their
behavior. PTMs are found in both eukaryotes and prokaryotes, being more common in
eukaryotes where about 5% of the genome is dedicated to enzymes that carry out more
than 200 types of PTMs45. PTMs are the attachment of specific chemical groups to amino
acid side chains that occur both enzymatically or nonenzymatically2,5. Examples include
phosphorylation, glycosylation, acetylation, methylation, sumoylation, palmitoylation,
biotinylation, ubiquitination, nitration, chlorination, glycation, nitrosylation, acetylation,
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and succination2,6. PTMs are important regulatory processes endowing proteins with the
functional complexity that is essential for the maintenance of protein homeostasis within
the cell.
Depending on the biological purpose of a modification on a specific protein
reversibility may or may not be beneficial. Reversible PTMs allow for control of intensity
and duration of the effect without the need to degrade the protein to end the desired
effect. Important functions of reversible posttranslational modifications include
maintenance of protein homeostasis as well as the ability of proteins to rapidly respond
to changing extracellular and intracellular signaling7.

Phosphorylation, acetylation,

ubiquitylation, and S-palmitoylation are forms of covalent modifications that are readily
reversed5. Reversible PTMs have dedicated enzymes, often large families of enzymes, that
catalyze the addition and/or removal of covalent modifications5. This allows for protein
regulation to occurring in both a spatial and temporal manner, which is vital for proper
regulation of signaling. Phosphorylation is the quintessential reversible modification
providing a good example of the importance and complexity of this type of dynamic
regulation.
Phosphorylation is the reversible addition of a phosphoryl group from adenosine
triphosphate (ATP) to primarily serine, threonine, or tyrosine residue and is broadly
considered the most common posttranslational modification2,8.

Phosphorylation

introduces a charged phosphate group which induces an altered conformational change
that can affect catalytic activity of proteins, the tendency of proteins to aggregate, and
the ability to recruit binding partners, all of which result in altered protein function and
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cell signaling2,5. This conversion of a neutral OH side chain to dianionic phosphate
provides a useful conformation switch in protein-domain restructuring, as such it has
evolved into the major recurring theme in eukaryotic proteome diversity5.
Protein kinases, which add the phosphate to a protein, remain in a basal “off”
state in the absence of a specific stimuli, once a signal is propagated, the kinases become
active and are able to modify their target proteins. Controlling the duration and intensity
of signal transduction is vital for proper protein signaling, as such the signals need to be
turned off and, in this case, phosphatases hydrolytically remove the PO32- group5. There
are approximately 500 kinases and 150 phosphatases encoded by the human genome
resulting in an almost infinite number of combinations creating amazing complexity9,10.
Lipidation is a general term encompassing the attachment of different lipids and
lipid-like groups onto proteins11. Protein lipidation is unique as it is structurally versatile
and directly controls the attachment of soluble proteins to cell membranes without the
requirement of other mediators4. Lipid modifications function to increase protein
hydrophobicity can impact protein structure, localization, spatial distribution, membrane
affinity, protein-protein interactions, and protein dynamics12. Covalent protein lipidation
can occur enzymatically or nonenzymatically. Among the many lipid classes enzymatic
modifications include myristylation, farnesylation, geranylation, and palmitoylation
shown in Table 1. Palmitoylation is unique as it is the only known reversible lipid
modification4. As such palmitoylation is crucial for the regulation of cellular plasticity due
to the effects on the physical properties of proteins which therefore alter protein activity,
localization, and membrane association.
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Additionally, lipid modifications can, and often do, work together to increase
intensity and duration of soluble protein membrane association5,13. Classically a single
lipid tether provides hydrophobicity for a strong but kinetically unstable association with
the membrane. Once another lipid is added there is a noticeable decrease in membrane
off-rates, from as fast as one minute with a single tether to as long as multiple hours once
another lipid is added. This greatly stabilizes the association of the protein with the
membrane and enables increase vesicular trafficking14,15.
Palmitoylation

S-acylation is a highly conserved process occurring in all eukaryotic organisms that
have been examined and regulated by enzyme families that are conserved from yeast to
humans. No evidence exists to show s-acylation occurs in prokaryotes, but many viral
proteins can undergo s-acylation by hijacking host cell machinery3. S-acylation is the
addition of a fatty acid, typically a saturated 16-carbon palmitate due to a combination of
availability and affinity, to cysteine residues via a thioester bond. Enzymatic
palmitoylation is catalyzed by palmitoyl acyltransferases (PATs) first identified in yeast.
Genetic and biochemical studies showed these PAT enzymes share a highly conserved
Asp-His-His-Cys domain termed the DHHC motif, resulting in these palmitoylating
enzymes often being referred to as DHHCs16–18.

5

Table 1. Types of Lipid Modifications

Table 1. Types of Protein Lipid Modifications. This table demonstrates the various
types of enzymatic lipid modifications, type of linkage, enzymes involved, and the lipid
species. Important to note is the addition of a palmitate to a cysteine residue is the
only known reversible lipid modification. Image copied with permission from
Chamberlain and Shipston, 2015.
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Palmitoylating Enzymes

The family of genes that encode the DHHCs are found in all eukaryotes with
numbers ranging from five in yeast to 23 in humans19. DHHC proteins are transmembrane
proteins with four to six transmembrane domains. The conserved DHHC motif located on
the cytoplasmic face between the second and third transmembrane domain and is
essential for enzymatic activity as it provides the necessary cysteine for the two-step
kinetic mechanism. To begin, the DHHC protein autoacylates using an acyl-CoA donor
forming a transient acyl-enzyme intermediate. Then the fatty acid, typically palmitate, is
transferred to the protein substrate20. The C- and N-terminal tails are highly varied and
typically contain domains involved in protein-protein interactions including, ankyrin
repeats, SH3 domains, and PDZ-binding motifs.
This variation likely contributes to the substrate specificity seen with DHHC
enzymes21,22. Some DHHC proteins appear to have a broad substrate specificity such as
DHHC3 which has been show to palmitoylate both soluble and transmembrane proteins
and is localized in the Golgi which is thought of as the hub of palmitoylation for soluble
proteins. DHHCs also display specific subcellular localization (Table 2) with the majority of
DHHCs residing in the ER and Golgi and a few found at the plasma membrane or in
vesicles23–25. Additionally, some DHHCs such as DHHC2 cycle between the endosomes and
plasma membrane26. This specific subcellular localization regulates access to substrates
and contributes to selectivity. More recently is has been found that certain DHHCs are
more common in specific tissues and others are expressed in only select tissues as can be
seen in Table 327. While the discovery of DHHCs as palmitoylating enzymes occurred in
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200216,17 many of the enzymes were already known to be involved in various physiologies
and diseases, as such they were given different names which are still often used. Some of
the most common examples include DHHC3, named GODZ, important for the
palmitoylation of AMPA and NMDA receptors thus playing a role in regulating the
excitation and inhibition balance in the brain which when abnormal could lead to various
neurological disorders25,28,29. DHHC17 was first identified as HIP14 (huntingtin-interacting
protein) and palmitoylates huntingtin, the major protein involved in Huntingtin Disease,
as well as other select neuronal proteins such as SNAP-25 and PSD-95. DHHC17/HIP14
plays an important role in regulating huntingtin and is implicated in the pathophysiology
of Huntingtin Disease25,30,31. Other DHHCs that are related to specific disease include,
DHHCs 6,9, and 21 implicated in Alzheimer’s Disease, DHHC8 in schizophrenia and bipolar
disorder, and DHHCs 9 and 15 in X-linked intellectual disability25.

Consequently,

understanding the regulation of palmitoylation via DHHCs is vital for understanding both
healthy physiology and disease.
Depalmitoylating Enzymes

In contrast to the more detailed study of DHHCs, much less is understood
regarding depalmitoylating enzymes. Palmitoyl protein thioesterase 1 (PPT1) is a member
of the α/β serine hydrolase family and was characterized as a thioesterase through
observations that it depalmitoylates H-Ras32. PPT1 localizes exclusively to lysosomes and
late endosomes which separates PPT1 from substrate targets in the cytosol or at the
plasma membrane33.
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Figure 1 DHHC Mechanism

Figure 1. DHHC Mechanism. For S-palmitoylation palmitic acid is transformed to
palmitoyl-CoA. The palmitoylating enzymes then use a ping-pong mechanism where
the palmitate group is transferred from the CoA to the open thiol in the DHHC region
of the palmitoylating enzyme creating a transient acyl-intermediate. The palmitate is
then transferred to the free thiol on the substrate resulting in a palmitoylated protein.
Image copied with permission from De and Sadhukhan, 2018.
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Figure 2 Schematic of DHHC Enzymes

Figure 2. Schematic of DHHC Enzymes. This figure shows representative isforms of
DHHCs showing their diversity and similarities. DHHCs all have the conserved DHHC
active site but can vary in the number of transmembrane domains, regulatory domain,
and binding sites. Image copied with permission from Tabaczar et al., 2017
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Table 2. DHHC Subcellular Localization

Table 2. DHHC Subcellular Localization. This table shows the known cellular localization
of the different DHHC isoforms. While most DHHC reside in the ER and Golgi some are
plasma membrane specific, with specific localizations such as neuronal spines and
presynaptic terminals. This localization compartmentalizes the DHHCs which likely
plays a role in regulating access to specific substrates. Image copied with permission
from Cho and Park, 2016.
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Table 3. DHHC Tissue Distribution

Table 3. DHHC Tissue Distribution. This table highlights that specific DHHC enzymes are
found in specific tissues. The same DHHC isoform may be found in multiple tissues
however not every DHHC is found in every tissue. This distribution may play an
important role in substrate access or change the available DHHC binding partners
regulating DHHC activity. Image copied with permission from Korycka et al., 2012.
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PPT1 dysfunction has been implicated in infantile neuronal ceroid lipofuscinosis,
a neurodegenerative disorder where lipid thioesters from acylated proteins accumulate
in the lysosome causing devastating decreases in motor skills and speech with the
development of seizures and death between age 9-1134. Palmitoyl protein thioesterase
2 (PPT2) is lysosomal specific and shares roughly 18% homology with PPT1. PPT2 is not
able to depalmitoylate the same proteins as PPT1 demonstrating that PPTs also display
substrate specify like PATs. Mutation of PPT2 also appears to cause a milder form of
infantile neuronal ceroid lipofuscinosis35. Due to the localization of PPT1 and PPT2,
neither are likely to contribute to depalmitoylation at the plasma membrane, instead
contributing to lysosomal degradation of palmitoylated proteins and potentially playing a
role in vesicular depalmitoylation.
Acyl protein thioesterases (APTs) are also members of the α/β serine hydrolase
family and were originally purified from rat liver as lysophospholipases (lypla). APTs can
hydrolyze multiple lysophospholipids and long-chain mono-acyl glycerol esters, at a much
lower catalytic efficiency than palmitoylated substrates36. Three isoforms have been
identified APT1, APT2 and APTL1 all of which are cytosolic proteins with the ability to
interact with internal membranes and the plasma membrane. APT1 and APT2 share 81%
homology and were originally thought to be redundant. Study of these enzymes have
been limited due to the lack of antibodies, leading to most studies being done with GFP
or HA tagged proteins. Overexpression of APT1 leads to decreased palmitoylation of small
GTPase, endothelial nitric oxide synthase, and other soluble proteins in cells37. Recent
studies have shown APT1 and APT2 are not redundant and do display substrate
13

specificity38,39. One interesting detail is that both APT1 and APT2 are palmitoylated, with
APT1 being able to depalmitoylate both isoforms and APT2 been shown to only
depalmitoylate itself but not APT1, adding complexity to the regulation of
palmitoylation.37,40. Use of inhibitors has aided in the study of endogenous APTs,
specifically the recent development of isoform specific inhibitors ML348 (APT1) and
ML349 (APT2)41. APTL1 is a homologue of APT1 with 31% similarity, however structurally
APTL1 is more similar to PPT2 with a narrow substrate binding pocket which prefers shortchain substrates. Currently, no protein substrates have been identified for APTL125.
While the study of APTs is ongoing and improving with the development of specific
antibodies, many researchers found that APTs and PPTs alone could not explain all
depalmitoylation. This reinvigorated the search for new depalmitoylating enzymes,
specifically within the α/β serine hydrolase family and resulted in the discovery that ABHD
enzymes can depalmitoylate proteins as well. Lin and Conibear found that ABHD17
depalmitoylates N-Ras, but not APT1 or APT242. Three isoforms, ABHD17A, 17B, and 17C
are also able to depalmitoylate PDS-9543. This indicates there may be more
depalmitoylating enzymes
Cellular and Physiological Roles of Palmitoylation

Palmitoylation is the only known reversible lipid modification, as such
palmitoylation plays an important role in the dynamic regulation of cellular proteins.
Palmitoylation of a protein can tether it to membranes as well as direct proteins to
specific membranes or membrane domains rich in cholesterol referred to as lipid rafts.
Soluble proteins such as the Ras family provide a classic example of proteins whose
14

localization is dynamically regulated by palmitoylation. H-Ras and N-Ras are palmitoylated
in the Golgi which then stabilizes their association with the membrane to facilitate
vesicular trafficking to the plasma membrane where they function as important signaling
molecules. Depalmitoylation at the plasma membrane then releases H/N-Ras to the
cytoplasm, ending the signaling in which they are involved and allows its return to the
Golgi, where the cycle can begin again15,44,45. Similar palmitoylation driven protein cycling
has been documented for multiple other signaling molecules include G-proteins, kinases,
synaptic proteins, and even depalmitoylating enzymes14,46–49. The rapid and dynamic
nature of palmitoylation is akin to phosphorylation. However, it should be noted that
rapid cycling of acyl chains on palmitoylated is not universal and low turnover rates can
occur3 adding to the complexity.
Palmitoylation of soluble membrane proteins promotes stable membrane
binding, which as mentioned above is important even for dual lipidated proteins as a
single myristoyl or prenyl group is not sufficient to provide a strong membrane
interaction. As the enzymes that mediate palmitoylation are exclusively transmembrane
proteins (see above) the weak association provided by a single irreversible lipid group is
likely important for mediating the interaction between soluble proteins and the
membrane to facilitate palmitoylation. Again, the Ras protein family provides an example
of this. When the palmitoylation sites are mutated Ras proteins still show a weak
association with the membrane, however when the farnesylation site is mutated loss of
both palmitoylation and membrane association is seen50. Combining palmitoylation, a
reversible lipid modification, with another irreversible lipid modification such as
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prenylation or myristylation is a powerful way to regulate soluble protein membrane
association as well as providing dynamic regulation of signaling proteins5,15,45,51. Of note
some soluble proteins are exclusively palmitoylated with no obvious primary membrane
targeting signals, such as SNAP25 an important component of the SNARE complex; it is
suggested that such proteins rely on weak intrinsic membrane affinity to undergo
palmitoylation52. Additionally two important neuronal proteins PSD-95, which functions
to scaffold glutamate receptors at the post-synaptic membrane, and GAP43, which is an
important component of the axonal growth cone rely solely on palmitoylation at multiple
cysteines for their membrane tethering with the combination of palmitoylation sites
being important for regulation of these factors14,15.
Lipids within cell membranes are diverse and can form microdomains rich with
cholesterol and saturated phospholipids, typically termed lipid rafts. Multiple studies
have been done to understand the physiologic importance of these lipid enriched areas,
with recent studies revealing palmitoylated proteins largely copurify with cholesterolenriched detergent-insoluble membranes.53 Further study showed palmitoylation plays
an important role as a regulator of lateral distribution of proteins within the membrane
and that palmitoylation is an important signal for sequestrating proteins to lipid rafts54.
This palmitoylation dependent association of proteins to lipid rafts regulates important
cellular pathways such as actin cytoskeleton remodeling via Rac155 and SNARE mediated
exocytosis via SNAP2556,57 demonstrating an important physiologic role for lipid rafts and
palmitoylation.
Palmitoylation is also known to increase protein stability by preventing
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ubiquitination thus decreasing protein degradation4,21. The interplay between
palmitoylation and ubiquitination was reported for Tlg1, a SNARE protein, where
palmitoylation alters the position of the transmembrane domain preventing acidic
residues from associating with the membrane which is a signal for Tul1-mediated
ubiquitination58. Additionally, proteomic analysis has been performed on mice with
reduced expression of palmitoylating enzymes noting that decreased palmitoylation of
proteins often correlated with an overall loss of expression3.
Palmitoylation effects the localization of soluble membrane proteins by
promoting accumulation of palmitoylated proteins on membranes containing the specific
palmitoylation and depalmitoylation enzymes that act on that protein. Palmitoylation can
also promote clustering of proteins within various membrane compartment as is the case
with Ras trafficking. This allows for Ras signaling to be compartmentalized, with different
Ras isoforms distributed within the Golgi stack based on di- and mono- palmitoylation
events which aid in the theory that Ras proteins signal from the Golgi4,59.
Since transmembrane proteins do not require palmitoylation for membrane
localization the role of palmitoylation in trafficking is more prevalent and potentially
easier to study than in soluble proteins. Trafficking from the ER after translation is
dependent on proper topological arrangement of the protein. Various chaperons and
enzymes in the ER lumen facilitate protein folding and catalyze modifications such as
glycosylation which are important for the assembly of proteins by facilitating folding,
subunit assembly and dimerization necessary for proper trafficking60. A large number of
palmitoylating enzymes are found in the ER indicating palmitoylation plays an important

17

role in proper protein assembly61. LRP6 is a single transmembrane protein that is
palmitoylated near the cytoplasmic side of the transmembrane region. When LRP6
palmitoylation sites are mutated the protein is retained in the ER, likely due to
hydrophobic mismatching that occurs between the transmembrane domain and the ER
bilayer. Palmitoylation reduces this mismatch by titling the transmembrane domain and
promoting trafficking of LRP6 to the plasma membrane62. Trafficking of membrane
proteins between the plasma membrane and endosomal system is also a common role of
palmitoylation, where the ability of a protein to be internalized can be altered by the
palmitoylation status as seen with AMPA and NMDA receptors. This is important to
consider as many proteins only function at the plasma membrane, thus studying
expression levels alone may not be sufficient to draw certain conclusions. In addition to
altering surface expression, palmitoylation can also affect endosomal accumulation of
proteins, such as MUC1, and impact protein cycling between endosomes and the Golgi as
seen with Sortillin3. Palmitoylation plays a clear role in protein trafficking of both soluble
and transmembrane proteins, leading to an important role for palmitoylation in
regulating protein expression, signaling, and function.
Palmitoylation plays an important role in protein localization and thus can
facilitate or inhibit protein-protein interactions. Palmitoylation can affect this interaction
through steric hindrance, conformational changes, and/or interaction of cytoplasmic
protein segments to the membrane interface. The generation of protein platforms
through palmitoylation creates dynamic multiprotein complexes which can contain both
palmitoylated and non-palmitoylated proteins. Oligomerization of proteins can also be
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promoted by palmitoylation, which can alter protein functionality63,64. Direct proof that
palmitoylation is required for the function of a given transmembrane protein can be
difficult to prove as function is often dependent on localization and protein interactions.
However, this does demonstrate the importance of palmitoylation in regulating both
duration and intensity of protein activity.
Typically, when a palmitoylation site is found in close proximity to a
transmembrane region the conformation of the domain and thus the function of the
protein can be altered. Palmitoylation can increase the hydrophobic length of the domain
and/or the orientation of the domain with respect to the bilayer. Tilting of the
transmembrane domains are important, especially when considering the thickness of the
membrane, as mentioned above with LRP6. Membrane thickness typically increases from
the ER to the Golgi to the plasma membrane; additionally, the curvature of the membrane
and cholesterol content can affect membrane thickness. If the transmembrane domain is
too long or too short, it can lead to a hydrophobic mismatch which can have detrimental
effects on the protein. Palmitoylation is typically used to reduce this mismatch by titling
the membrane and allows for proper processing especially from the ER to the Golgi.
Palmitoylation, like phosphorylation, has been implicated in a diverse range of
physiological processes. These processes include but are not limited to synaptic plasticity,
host-pathogen interactions, innate immunity, cell death, metabolism, cell polarity and
migration, and membrane trafficking. As palmitoylation affects so many vital cellular
processes it can be implicated in almost any disease either directly or indirectly, making
understanding the regulation of proteins by palmitoylation important for numerous
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pathologies.
Sodium Hydrogen Exchanger Isoform 1 (NHE1)

Similar to how palmitoylation can be implicated in a broad range of diseases
ubiquitously expressed proteins, especially those that regulate basic cellular functions,
are also implicated either directly or indirectly in a broad range of diseases. Intracellular
pH (pHi) is one of these basic systems that is regulated by the sodium hydrogen exchanger
isoform 1 (NHE1). NHE1 is a ubiquitously expressed transmembrane protein that
exchanges an intracellular hydrogen for an extracellular sodium to regulate pHi and
control cell volume65. The study of NHE1 was greatly enhanced when Pouyssegur et al
used a highly specific proton suicide technique on Chinese hamster lung fibroblast
(CCL39), which express only isoform 1 of NHE, to create mutant cells lacking NHE1
expression (PS120)66. Later human NHE1 was transfected into these cells resulting in the
PSN cell line which now expresses human NHE1 as the main regulator of pHi, making these
cell lines the gold standard to study NHE1 activity via pHi measurement.
NHE1 Physiology

Regulation of pH and control of cell volume are the most basic roles of NHE1 these
factors also have wide ranging implications on many cell processes such as cell migration,
cell proliferation, vesicle trafficking, apoptosis, cell survial67 and cell metabolism68,69. In
fibroblast type cells NHE1 preferentially localizes to the leading edge of lamellipodia,
where ion transport creates an alkaline intracellular environment paired with an acidic
extracellular environment. This allows for actin stress fibers to form at the membrane70
while simultaneously aiding in the degradation of the extracellular matrix allowing for

20

increased cell migration and invasion. Multiple studies have shown that the presence of
NHE1 is essential for proper directional cell migration71,72. Recently, NHE1 has been
shown to play a role in lysosome trafficking to the cell periphery in the prostate73.
Additionally, NHE1 acts as a protein scaffold, binding many partners including PIP2, ERM,
calmodulin and CHP1/2 and various posttranslational modifications74,75. Through this
scaffolding, NHE1 contributes to various cell signaling processes in ion independent and
dependent manners with the binding of proteins and addition of modifications having
been shown to alter transport activity76–78.
NHE1 has also been well researched in specific organ systems, especially the
cardiovascular system where NHE1 is a central regulator of cardiomyocyte pHi and
contractility79 and is localized to the plasmalemma, intercalated discs, and transverse
tubules. Cardiac pHi changes during increased cardiac workload and heart rate with
increased NHE1 activity contributing to cardiac ischemia-reperfusion damage and
hypertrophy80. NHE1 is also found in the vasculature in both smooth muscle and
endothelial cells. Based on several studies in mice and cells, NHE1 is thought to play a role
in pulmonary artery remodeling, angiogenesis, volume control and fibronectin
production76,81. NHE1 is also essential for the central nervous system, where studies using
NHE1 knockout mice show abnormal neuronal excitability, epilepsy from Na+
permeability, and death before weaning. Other studies show NHE1 playing a role in
several neurological diseases including dementia, specifically Alzheimer’s Disease,
neuropathic pain, and cerebral ischemia82. In the central nervous system (CNS) NHE1
regulates pHi in neurons, glial cells, and microvascular endothelial cells. The mechanisms
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surrounding the role of NHE1 in the CNS are largely unknown. Most studies have focused
on the role NHE1 plays in glioblastoma multiform, an aggressive cancer of the glial cells,
as the role of NHE1 in cancer has been clearly established83–85. A number of mitogenic
factors have been shown to activate NHE1 resulting in increased cell growth,
proliferation, migration, and invasion, all processes important for the neoplastic
transformation and maintenance of malignant cells. The pHi of malignant cells is more
basic than that of the corresponding nontransformed cells, thus disturbance of pH
homeostasis has been thought to correspond to an increased cancerous state86. NHE1 has
been implicated in a number of cancers apart from glioblastoma, including but not limited
to breast87,88, prostate89, ovarian, and lung90,91. Recent interest has surrounded the role
NHE1 plays in activation of brain microglial cells and how this may contribute to brain
focal ischemia92. In addition, activation of brain microglia and increased inflammation has
been shown to play a role in neurodegenerative disease, specifically Alzheimer’s Disease,
indicating NHE1 could play a bigger role in neurological diseases than originally thought.
Furthermore NHE1-mediated pH-regulation has been shown to be important for IgEinduced macrophages and correctly functioning neutrophils76,93,94.
NHE1 Structure

Human NHE1 (hNHE1) is an 815 amino acid protein with the first 500 residues
making up 12 transmembrane spanning segments with interconnecting loops and the last
315 comprising an intracellular tail. Due to the difficulties associated with crystallizing
membrane proteins, relatively little is known about the structure of NHE1. Some insight
has been provided by the crystallization of the E. Coli Na+/H+ antiporter (NhaA) by Hunte
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et al (2005) which shows structural similarity to hNHE195,96. Additional various molecular
biology techniques have been employed to gain a general understanding of NHE1
structure. Substituted-cysteine-accessibility analysis was used to confirm the 12 TM
domain topology and that the N- and C-termini were cytosolic. It also identified three
membrane associated regions, intracellular loop 2 (IL2), intracellular loop 4 (IL4) and
extracellular loop 5 (EL5), which may be important in for NHE1 function. The transport
function of NHE1 occurs in the N-terminal half of the protein (first 500 residues) with TM
IV, TM VII, TM IX, and TM XI containing residues that are important for ion binding and
transport97. The C-terminal region (315 amino acids) is completely intracellular and
considered the regulatory domain of NHE1. The membrane proximal region (503-685)
termed the predicted folded domain is 50% random coil with 35% of that being a-helix
and the membrane distal domain (686-815) being intrinsically disordered98,99. The
proximal region contains multiple protein binding sites while the distal region has multiple
phosphorylation sites which operate to regulate NHE1 function and are described in
greater detail below.
NHE1 Binding Partners

Phosphatidylinositol 4,5-bisphosphate (PIP2) is a signaling phospholipid at the
plasma membrane that can be converted into other signaling molecules that are
important 2nd messengers. NHE1 has two PIP2 binding sites (513-520 and 556-564) and
studies show loss of PIP2 binding inhibits NHE1 function making the NHE1-PIP2 interaction
important for proper regulation69,100,101. Calcineurin homologous protein 1 (CHP1) also
binds NHE1 in the proximal membrane region between residues 510-530. The association
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between CHP1 and NHE1 is essential as interrupting this interaction results in a dramatic
loss of NHE1 activity102. Overexpression of CHP1 in fibroblast cells leads to inhibition of
serum stimulated proton transport, while mutations of the CHP1 binding site on NHE1
reduce proton sensitivity and decrease NHE1 activity103,104. It is thought that the CHP1NHE1 interaction promotes an NHE1 structure with a more available proton sensing
domain, preserving pHi sensitivity of NHE1101. Additionally, CHP2, which is highly
expressed in tumor cells, interacts with NHE1 and protects cells from serum deprivation
induced cell death by increasing pHi to maintain the malignant state of transformed
cells103.
Ezrin, radixin, and moesin (ERM) proteins form a complex at the plasma
membrane that provides an important link between the plasma membrane and actin
filaments that form the cytoskeleton. NHE1 contains two ERM binding domains on the Cterminal tail between residues 553-564 which directly mediates this interaction105. The
cellular cytoskeleton is essential for maintaining cell shape and establishing mechanical
and chemical properties within the plasma membrane. The ERM -NHE1 interaction directs
NHE1 localization in the lamellipodia of migrating cells and if this interaction is disrupted,
cells develop an irregular shape and have limited motility71. Additionally, the physical
interaction of ERM proteins and NHE1 activates Akt, a pro-survival kinase which leads to
stalled apoptosis75,106. Calmodulin (CaM) is a calcium binding protein that binds NHE1 to
regulate pHi in response to calcium signaling. Binding of calcium and calmodulin to the
high affinity site on NHE1 (636-656) activates NHE1 by blocking the autoinhibitory
interaction thus regulating intercellular pH107. NHE1 also has three consensus sites for N-
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linked glycosylation, N75, N370, and N410. Interestingly mutation of all three sites,
individually and in combination, produced functional transporters with similar transport
rate and pharmacological profiles to the wild type exchanger, however cleavage using
endoglycosidase does result in reduced apparent size of NHE1 from 110kDa to
90kDa108,109.
NHE1 Phosphorylation

NHE1 regulation by phosphorylation has been widely studied. Bioinformatic and
mass spectrometry analysis has predicted multiple phosphorylation sites on the Cterminal tail focused mostly on the distal end. Many of these phosphorylation sites have
been experimentally validated along with the kinases involved and various stimuli
including hormones, growth factors, and sustained intracellular acidosis97. Growth factor
stimulation of fibroblast cells induces the MAPK (mitogen-activated protein kinase)
cascade resulting activation of ERK1/2 (extracellular-signal-regulated kinase) leading to
NHE1 activation. Inhibition of the ERK signaling cascade reduces growth factor stimulated
NHE1 activation by 50-60%, a similar reduction is seen when ERK sites on NHE1
(S770/771) are removed110. ERK2 also stimulates phosphorylation on S693, S766, S770,
and S785, however, the importance of these residues needs to be further explored. ERK
is also an upstream regulator of Rsk (p90 ribosomal S6 kinase), which phosphorylates
NHE1 at S703111. Both the ERK and Rsk sites are important for invasion and migration of
breast cancer cells. Additionally, the Rsk site (S703) can act independently of the ERK sites
to control movement of tumor cells into and out of the circulatory system which is
important for cancer metastasis112,113. Interestingly, stimulation of fibroblast cells with
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platelet derived growth factor (PDGF), which activates the ERK/Rsk pathway, results in
NHE1 mediated cell migration and cytoskeletal formation but not alteration of NHE1
transport activity114. AKT phosphorylation is also required for NHE1 activation through
PDGF stimulation. AKT phosphorylates NHE1 at S648 and activates NHE1 in fibroblasts,
however, AKT phosphorylation of NHE1 in cardiomyocytes has an inhibitory effect70.
ROCK (Rho-associated kinase p160ROCK) is a downstream target of RhoA (GTPase)
which stimulates NHE1 via direct phosphorylation at T653. Both the ROCK and ERK
pathways are required for full activation of NHE1 through growth factor receptor
stimulation98. Apoptotic signals stimulate MAPK p38 which induces intracellular
alkalization activating NHE1 through phosphorylation at potential sites including T718,
S723, S726, and S729115,116. Platelet derived growth factor activates NHE1 via NIK (Nckinteracting kinase) phosphorylation at S638114,117. NHE1 activation through phorbol ester
stimulation has also been shown, however, no direct PKC phosphorylation sites on NHE1
have been found118,119. In addition, acidification stimulates CaMK II (Ca2+/calmodulindependent kinase II) medicated NHE1 phosphorylation and contributes to increased
NHE1 activity. Several other kinases including PKA, Raf, Pyk2 and Daxx have been found
to bind and phosphorylate NHE1 but specific residues have not been found120. Figure 3
displays these phosphorylation and binding partner sites on NHE1. Overall NHE1 is a
highly modified protein, which is important for regulating activity as well as localization,
protein scaffolding, and protein-protein interactions. Proper regulation of NHE1 is vital
for maintaining cellular homeostasis. The presence of multiple cysteine residues on the
C-terminal tail of NHE1 combined with its highly modified nature lead us to explore NHE1
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palmitoylation and the role the regulation plays physiologically.

Dissertation Research Objective
The objective of this dissertation is to demonstrate NHE1 is palmitoylated and
inhibition of palmitoylation alters NHE1 associated physiology. As well as show
preliminary evidence that multiple phosphorylation pathways that act to alter NHE1
palmitoylation indicating palmitoylation and phosphorylation work in a coordinated
manner to regulate NHE1.
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Figure 3 Schematic Model of NHE1

Figure 3. Schematic Model of NHE1. This NHE1 diagram highlights the C-terminal tail
showing the large number of phosphorylation sites and kinases involved. Also shown
are various biding partners and their subsequent binding sites. Copied with
permission from Wallert et al., 2016.

28

Chapter II
FUNCTIONAL CONSEQUENCES OF INHIBITING SODIUM HYDROGEN
EXCHANGER 1 (NHE1) PALMITOYLATION
Abstract
Palmitoylation is a reversible lipid modification that regulates an array of protein
functions including activity, trafficking, membrane microlocalization and protein-protein
interactions. Identification of over 5000 proteins with this modification suggests that
palmitoylation plays a critical role in regulation of many cellular processes. In this study
we demonstrate for the first time a member of the SLC9 family, the sodium hydrogen
exchanger isoform 1 (NHE1), is palmitoylated in both cells and rat tissue. In addition,
using the irreversible PAT inhibitor 2-bromopalmitate (2BP) we have identified several
cellular functions commonly associated with NHE1 are affected by decreased NHE1
palmitoylation. Treatment of Chinese hamster lung fibroblast cells expressing human
NHE1 with 2BP results in decreased palmitoylation. This treatment also resulted in
decreased NHE1 activity, detected by measuring the change in intracellular pH.
Additionally, PSN cell migration and proliferation was inhibited by 2BP in a manner
consistent with the degree of inhibition of NHE1 palmitoylation. These results suggest
that palmitoylation plays a major role in NHE1 regulation that could significantly impact
multiple critical cellular functions.
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Introduction
The SLC9 transporter family is made up of transmembrane sodium hydrogen
exchangers which function to regulate intracellular pH (pHi) by exchanging an intracellular
proton for an extracellular sodium ion in various tissues75. Sodium hydrogen exchanger
isoform 1 (NHE1) functions at the plasma membrane and is ubiquitously expressed
throughout tissues121,122. Multiple cellular processes are associated with NHE1 activity
including coordinated cell migration, cellular proliferation, and control of cell volume.
NHE1 also functions as a membrane anchoring and scaffolding protein resulting in the
formation of different protein complexes that participate in regulating signaling pathways
within the cell123,124.

Regulation of NHE1 activity and function occurs within the

regulatory domain found on the large intracellular C-terminal tail. Many binding partners
and modifications occur within this regulatory domain and influence exchanger activity
and trafficking. Major binding partners include PIP2100 and ERM71 which are important for
association of the tail to the inner membrane leaflet and the formation of stress fibers,
respectively123. Ca2+/calmodulin binding sites also on the C-terminal tail have been shown
to play an important role in proton affinity and thus regulate NHE1 activity107.
Additionally, multiple phosphorylation sites are also present on the C-terminus which
have varying effects on NHE1 activity and the multiple cellular processes in which NHE1
plays a role. Together these many regulatory factors control NHE1 activity, localization,
and expression, all of which are important for regulation of critical cellular processes.
S-Palmitoylation is the addition of a 16-carbon fatty acid to a cysteine residue via a
thioester bond. Palmitoylation is a unique lipid modification because it is reversible, with

30

palmitoyl acyltransferases (PATs) adding the palmitate while acyl protein thioesterases
(APTs) and palmitoyl-protein thioesterases (PPTs) remove the palmitate. The most well
studied function of palmitoylation is trafficking of proteins between the organelles and
increasing membrane association of cytosolic proteins. Recent studies have
demonstrated that palmitoylation has multiple other effects on proteins, particularly
transmembrane proteins where effects include regulation of protein activity, membrane
microlocalization and protein-protein interactions125,126. Dysregulation of protein
palmitoylation has been implicated in neurological dysfunction including Huntington and
Alzheimer’s disease, multiple forms of cancer and many other diseases26,127–130.
Due to the highly modified nature of the NHE1 C-terminal tail and the presence of
multiple cysteine residues which are potential sites of palmitoylation we hypothesized
that palmitoylation could be present on NHE1 playing a role in regulating activity and
associated cellular functions. Using acyl biotinyl exchange (ABE) and metabolic
incorporation of [3H]palmitate we showed NHE1 is palmitoylated in both cells and various
rat tissues. Additionally, we used 2-bromopalmitate (2BP), an irreversible inhibitor of
palmitoylating enzymes (PATs)131, to decrease palmitoylation of NHE1 in a time
dependent manner. Using 2BP to decrease palmitoylation we also showed a decrease in
pHi indicating palmitoylation plays a role in regulation of NHE1 activity. Additionally,
stress fiber formation, cell migration, and cell proliferation were decreased upon 2BP
treatment, all critical cellular functions regulated by NHE1. Together these data establish
a role for the reversible lipid modification, palmitoylation, in the regulation of NHE1
activity and associated cellular functions.
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Materials
Colorburst molecular mass standard, 2- bromopalmitate (2BP), and mouse antiflag tag antibody were from Sigma Millapore and anti-NHE1(54) mouse monoclonal
antibody

(sc-136239)

was

from

Santa

Cruz

Biotechnology.

MMTS

(N-(6-

(biotinamido)hexyl)-3-(2-pyridyldi-thio)-propionamide), high capacity NeutrAvidin ®agarose resin, and bicinchoninic acid protein assay reagent was from Thermo Scientific.
HPDP-biotin

was

from

APExBio,

BCECF-AM

2ʹ,7ʹ-bis-(carboxyethyl)-5-(and-6)-

carboxyfluorescein was from Molecular Probes and Nigericin was from Tocris Bioscience.
LPA in the form of 14:0 1-myristoyl-2-hydroxy-sn-glycero-3phosphate (sodium salt) was
from

Avanti

Polar

Lipids

and

XTT(2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-

tetrazolium-5-carboxyanalide) reagent from Trevigen.
Methods
Cell Culture

NHE1-null cells (PS120 cells, a gift from D. Barber, University of California, San
Francisco) derived from Chinese hamster lung fibroblasts CCL339 were used to generate
a stably expressing human NHE1 with HA DDK epitope tag on the C terminus labeled PSN
cells. These cells were maintained in Dulbecco’s modified Eagle medium (DMEM)
supplemented with 20% fetal bovine serum, 2 mM L-glutamine, and 200 µg/ml G418 at
37oC in a humidified 5% CO2 incubator after clonal isolation 98.
Cell Treatments and Membrane Preparation for Palmitoylation Detection
PSN cells were subcultured, seeded on 150 mm culture dishes, and grown to
confluency and treated with experimental treatment conditions as described. After
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treatment, cells were washed twice with 3 mL of ice-cold buffer B (0.25 M sucrose, 10
mM triethanolamine, 10 mM acetic acid, pH 7.8) and then scraped to one side of the plate
using 0.5 mL of buffer B and transferred to a 2 mL microcentrifuge tube on ice. Cells were
then pelleted by centrifugation at 3,000 x g for 5 min at 4oC. The supernatant fraction was
removed and 1 mL of ice-cold buffer C (0.25 M sucrose, 10 mM triethanolamine, 10 mM
acetic acid, 1 mM EDTA, pH 7.8) containing protease inhibitor was added to break the
pellet loose. The solution containing the loose pellet was then homogenized in a Dounce
homogenizer with 30 up and down strokes on ice. The resulting homogenate was
centrifuged at 800 x g for 10 min at 4°C to pellet and remove nuclei and cell debris. The
supernatant fraction was transferred to a new tube which was centrifuged at 16,000 x g
for 12 min at 4°C to precipitate cell membranes. The supernatant fraction was removed
and the pellet containing cell membranes was resuspended in 1 mL sucrose-phosphate
(SP) buffer (10 mM sodium phosphate, 0.32M sucrose, pH 7.4) and assayed for protein
content.
Metabolic Labeling of NHE1 with [3H]Palmitate

PSN cells were metabolically labeled with [9,10-3H]Palmitic acid (0.5 mCi/ml) for
indicated times at 37 °C in a-MEM, containing 1 mM sodium pyruvate to inhibit palmitate
metabolism through fatty acid -oxidation132,133. After labeling, cells were washed with SP
buffer and lysed in radioimmunoprecipitation assay buffer (RIPA; 10 mM sodium
phosphate, 150 mM NaCl, 2 mM EDTA, 50 mM sodium fluoride, 1% Triton X-100, 1%
sodium deoxycholate, 0.1% SDS, pH 7.2). Lysates were then immunoblotted with antiDDK to determine NHE1 levels and volumes containing equal amounts of NHE1 (verified
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by a second immunoblot) were immunoprecipitated with anti-DDK protein A beads.
Precipitated NHE1s were resolved on 4-20% SDS-polyacrylamide gels, treated with
Fluoro-Hance (Research Products International) fluorographic reagent for 30 min, dried,
and exposed to x-ray film for ~ 60 days.
Palmitoylation Detection using Acyl-Biotinyl Exchange (ABE)

Adapted from Wan et al134 palmitoylated proteins are detected using three steps.
(i) Free cysteine thiols are blocked; membranes isolated from PSN cells were solubilized
in lysis buffer (50 mM HEPES pH 7.0, 2% SDS (w/v), 1 mM EDTA) containing protease
inhibitors and 20 mM methyl methanethiosulfonate (MMTS) and incubated for 20
minutes at 37oC, followed by acetone precipitation. Precipitated proteins were again
solubilized in lysis buffer containing protease inhibitors and MMTS and incubated at room
temperature with end over end mixing overnight. MMTS was removed by three
consecutive acetone precipitations in which the protein pellet was resuspended in 4SB
buffer (4% SDS, 50 mM Tris, 5 mM EDTA, pH 7.4) followed by acetone precipitation. (ii)
Thioester linked palmitoyl groups are specifically removed by hydroxylamine (HAM); The
resuspended protein sample is split equally into negative control (50 mM Tris-treated)
and HAM-treated (0.7 mM) halves and incubated at room temperature for 15 min with
end-over-end mixing. (iii) The previously palmitoylated and now free sulfhydryl groups
are then biotinylated by the addition of sulfhydryl specific HPDP-biotin (0.4 mM, 50 mM
Tris-HCl, pH 7.4) for 1 h at room temperature with end over end mixing, HAM and
unbound biotin was removed with three sequential acetone precipitations; the
biotinylated proteins were then affinity purified using NeutrAvidin® resin. Bound proteins
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were eluted, subjected to SDS-PAGE, and immunoblotted with mouse anti-Flag M2
primary antibody to detect tagged NHE1.
Live/Dead Cell Assay

PSN and PS120 cells were grown in media with the indicated 2BP concentrations
and cell viability was were assessed using the viability/cytotoxicity assay from
ThermoFisher. Live cells were counted after staining with calcein-AM while dead cells
were determined by uptake and staining with ethidium homodimer-1.
Cell Proliferation Assay

Cell proliferation assay was performed by the reduction of XTT (2,3-bis(2methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxyanalide). Cells were plated at
2,500 cells/well in a 96-well plate and incubated for 4 h to allow for attachment. Then the
cells were incubated in DMEM media containing 0.5% FBS with the indicated agonist or
inhibitors. After 48 h, activated XTT reagent was added to each well to attain a final
concentration of 0.3 mg/mL and absorbance was read at 450 nm and 690 nm.
Intracellular pH Determination

Steady-state intracellular pH (pHi) was measured using 2ʹ,7ʹ-bis-(carboxyethyl)-5(and-6)-carboxyfluorescein (BCECF), a pH-sensitive fluorescent dye. Cell monolayers were
cultured in multi-well dishes in either 20% or 0.5% serum and treated with experimental
treatment conditions as described. Prior to pHi determination, cells were incubated with
10 µM BCECF in PBS for 10 min at 37oC and 5% CO2. BCECF solution was replaced with
treatment condition media to remove free dye and incubated at 37oC and 5% CO2for 10
min at before imaging. Fluorescence was measured using a fluorescent plate reader
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(ThermoFisher Scientific Fluoroskan Ascent Fluorescence 96/384 Well Plate Reader) at
440:527 and 485:527 nm excitation: emission corresponding with pH independent and
pH dependent regimes of BCECF excitation respectively. pHi was calculated by taking the
fluorescence intensity ratio of pH independent over pH dependent fluorescence
compared to an internal K+-Nigericin calibration curve from each well. Curves were
generated by incubating cells in buffered 50 µM Nigericin at pH 6.5 and pH 7.5 for 5 min
followed by the measurement of BCECF fluorescence.
Stress Fiber Formation

Cells were grown on quartz coverslips and following the indicated treatment were
fixed with 3% paraformaldehyde at 4oC for 30 min and permeabilized with a 0.4% (v/v)
solution of Triton-X100 in water for 10 min. Actin stress fibers were stained with 0.5
µg/mL phalloidin-Alexa Fluor 488 for 60 min in a humidified container. Prior to mounting,
prolong anti-fade reagent was applied. Cells displaying significant and strong stress
fibers98 were counted in five random fields for each slide.
Electric Cell-substrate Impedance Sensing (ECIS) Migration Assay

Using the ECIS Z system (ECIS® Z, Applied Biophysics Inc.), impedance was
measured to characterize migration rates in cultured cells. Cells were seeded at 100,000
cells/well in 8-well arrays (8W1E-PET) in DMEM medium containing 0.5% FBS and allowed
to attach for approximately 21 h. Cells were then treated with 15 µM 2BP for 18 h after
which a 20 sec. 16,000 Hz shock was sent to the 250 µm diameter electrode located in
the middle of each well. Cell death occurs only to the cells attached to the electrode and
then impedance was measured in real-time as cells migrated onto the electrode.
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Wound Healing Assay

Cells were seeded to each well of culture inserts (Ibidi) and incubated for
attachment and until complete confluence at 37oC in a humidified 5% CO2 incubator.
Twelve h prior to removal of the culture insert, cells were treated with the indicated
concentrations of either DMSO (control) or inhibitor before removal of insert. Images of
each wound was collected at the indicated time point and determined at four sites.
Results are presented as an average of four trials repeated 2-3 times. The percent wound
remaining was calculated as compared to each initial wound.

Results
NHE1 is Palmitoylated in PSN Cells and Rat Tissues.

Palmitoylation occurs on intracellular cysteine residues and regulates many functions
including protein trafficking, membrane microdomain localization, and protein activity.
NHE1 is a versatile protein that requires specific membrane microdomain localization and
trafficking and is also highly modified by phosphorylation. Upon examination of the
human NHE1 sequence we found five intracellular cysteines, with three residing on the
highly modified C-terminal tail. Taken together, this information led us to speculate that
NHE1 may be a palmitoylated protein.
To test this hypothesis, we used PSN cells which stably express human NHE1 and
various rat tissues including brain, lung, liver, and heart to explore NHE1 palmitoylation
utilizing an acyl biotinyl exchange (ABE) method. The ABE process is an in vitro assay for
post-hoc detection of endogenous palmitoylation. In short, the ABE is done by removing
endogenous acyl thioesters using hydroxylamine (HAM) and replacing them with a
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sulfhydryl-specific biotinylating reagent (HPDP biotin). Control samples treated with Tris
in place of HAM do not incorporate the sulfhydryl reagent, demonstrating the specificity
of labeling. Figure 4 is a representative western blot of NHE1 demonstrating the ABE
palmitoylation assay. The presence of NHE1 in the in the HAM fraction (Palm NHE1, Fig
4A) is representative of palmitoylated NHE1, while the absence of NHE1 in the negative
control Tris fraction (Tris Control, Fig 4A) shows there was no non-specific incorporation
of HPDP-biotin nor nonspecific binding to the NeutrAvidin™ resin. Additionally,
immunoblotting samples of the HAM and Tris treated fractions for NHE1 prior to
NeutrAvidin™ chromatography shows total NHE1 levels were not changed by the HAM
exposure. To confirm this finding, we used metabolic labeling of PSN cells with
radiolabeled palmitic acid132. After labeling with 10 µM [3H]palmitic acid for 1-6 h, NHE1s
were extracted by immunoprecipitation and subjected to SDS-PAGE followed by
fluorography (Fig. 4B). A [3H]palmitate-labeled band appeared at a mass of ˜90kDa, the
monomeric mass of NHE1. An additional band was present slightly below 90kDa
representing the immature non glycosylated form of NHE1. Time course studies show
[3H]palmitate labeling of NHE1 was scarcely detectable within 1 h and increased in
intensity after 3 and 6 h of metabolic labeling indicative of rapid palmitate turnover.
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Figure 4 S-Palmitoylation of NHE1

Figure 4. S-Palmitoylation of NHE1. Determination of NHE1 palmitoylation was
confirmed by acyl biotin exchange (ABE) in lysates from various rat tissues and PSN
cells (A) as well as by [3H]palmitic acid labeling in PSN cells (B). A, Lysates were
treated with Tris or hydroxylamine (HAM) and immunoblotted for NHE1. NHE1 in
the total portion of the immunoblot shows NHE1 present in the lysate. The presence
of NHE1 in the HAM fraction (top panel) shows NHE1 is modified by acylation. The
lack of NHE1 in the negative tris control fraction indicates only NHE1 modified by an
acyl thioester was detected by the assay. (B) PSN cells were metabolically labeled
[3H] palmitic acid for indicated times. Cells were lysed and immunoprecipitated with
anti-NHE1 followed by SDS-PAGE/fluorography. The top panel shows [3H]palmitic
acid incorporated into NHE1 showing NHE1 is palmitoylated consistent with the ABE.
Results are show as representative western blots of three independent experiments.
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Inhibition of NHE1 palmitoylation

To further evaluate NHE1 palmitoylation we utilized 2-bromopalmitate (2BP), a
well-known irreversible inhibitor of palmitoyl-acyl transferase enzymes (PATs), which
catalyze the addition of palmitate to proteins. To begin, we assessed the potential toxicity
of 2BP on lung fibroblast cells (PSN). These cells, derived from NHE null PS120 fibroblasts,
are stable expressers of epitope tagged WT human NHE1135,136. This allows us to identify
specific NHE1 related functions as no other NHE isoforms are expressed in the parental
cell line98. Figure 5 shows that after treatment with either 20 µM or 50 µM 2BP, cells
showed a minimal decrease in cell viability (5A and B) and the PSN cells began to lose
viability only after 70 h of treatment (5A). A similar effect was observed in non NHE1
expressing cell lines (5B). Incubation of both PSN and PS120 cells with the corresponding
concentrations of palmitate had no effect on cell viability as expected, clearly indicating
that potential changes in cell physiology after 2BP treatment would not be due to acute
toxic effects. As PSN cell viability was not affected by 2BP treatment during the 18 h time
frame, we began to assess NHE1 palmitoylation by treating PSN cells with a low
concentration of 2BP (1 µM) for various time points. Here we saw a stepwise decrease in
NHE1 palmitoylation from 1 h to 18 h (All p<0.05 vs. NT; 0.5 h p<0.05 vs. 9 h and 18 h)
without the loss of total NHE1 levels (Fig. 6A). For palmitoylation analysis via ABE, control
samples treated with Tris in place of HAM did not incorporate the sulfhydryl reagent,
demonstrating

the

specificity

of

palmitoylation

site

labeling.

Additionally,

immunoblotting showed that total NHE1 levels were not changed by the 2BP incubation
or HAM exposure (p>0.05). These results demonstrate that 2BP suppresses
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palmitoylation of NHE1 at low concentrations, which are not toxic to the cells, and this
suppression occurs in a time dependent manner consistent with the enzymatic nature of
palmitoylation. To determine if increased concentrations of 2BP would further reduce
NHE1 palmitoylation without reducing total NHE1 expression or affecting cell viability we
treated cells with a range of 2BP concentrations for 18 h (6B). We found 2BP equally
decreased NHE1 palmitoylation at 1 µM, 5 µM, 10 µM and 15 µM without reduction of
total NHE1 levels (Fig. 6B). This established effective concentrations and incubation times
in which NHE1 palmitoylation is reduced by 2BP without the reduction of total NHE1
protein or cell toxicity, allowing us to move forward confidently using 2BP within these
ranges and time frames to treat PSN cells and monitor the effects of 2BP on NHE1
mediated cellular processes.
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Figure 5 2BP Reduces Cell Viability Only at High Concentrations for Extended Periods of Time

Figure 5. 2BP Reduces Cell Viability Only at High Concentrations for Extended
Periods of Time. Viability of PSN and PS120 cells was assessed after incubation with
20 µM or 50 µM 2BP. A, PSN cell viability decreased only after over 70 h of 2BP while
incubation with palmitate had no effect on cell viability. B, 2BP treatment of PS120
cells which do not express any isoforms of NHE only slightly decreased cell viability
after 70 h, with palmitate having no effect.
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Figure 6 Inhibition of NHE1 Palmitoylation

Figure 6. Inhibition of NHE1 Palmitoylation. PSN cells were treated with 1 µM 2BP for
the indicated time (A) and indicated concentration for 18 h (B) to show inhibition of
NHE1 palmitoylation. The western blots representative at least three independent
experiments performed to analyze acyl thioester content. The top panel of the
western blot represents acyl modified NHE1, measured by ABE assay. The lower panel
of the western blots shows total NHE1 in the samples after having undergone ABE
which is used to normalize palmitoylated NHE1. The decrease in NHE1 palmitoylation
begins within 30 min with a 25% decrease and continues in a stepwise manner to a
50% decrease at 18 h. When the concentration of 2BP is increased up to 15µM NHE1
palmitoylation remains decreased by approximately 50%. Quantification of NHE1
palmitoylation mean ± SD of at least three independent experiments performed in
duplicate relative to control (CNT), * < p 0.05, ** < p 0.01 *** < p 0.001 versus NT (oneway ANOVA with Tukey’s post hoc test).
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NHE1 Transport Capacity is Decreased in Response to Palmitoylation Inhibition

To examine the effect of 2BP on NHE1 activity, changes in intracellular pH (pHi) were
measured using 2ʹ,7ʹ-bis-(carboxyethyl)-5-(and-6)-carboxyfluorescein (BCECF) in PSN cells
after treatment with increasing concentrations of 2BP for 18 h. pHi significantly decrease
by 0.13 ± 0.04 and 0.25 ± 0.04 pH units in the presence of 10 µM or 15 µM 2BP,
respectively, compared to vehicle indicating acidification of the cells and decreased
capacity of NHE1 in maintaining cellular pH since it is the primary proton transporter in
these cells.
LPA is a well-known activator of NHE1 transport98, as such, we examined the impact
of reduced NHE1 palmitoylation in the presence of 2BP on LPA-stimulated NHE1 transport
to provide initial insight on the role of lipid modifications on NHE1 regulation and function.
As seen in previous work under serum starved conditions (0.5% FBS)98,137, incubation with
10 µM LPA led to a 0.18 ± 0.03 increase in pHi (Fig 7B). Under these same serum
conditions, pretreatment of PSN cells with 5 or 15 µM 2BP for 18 h significantly muted the
LPA stimulated NHE1 response (Fig 7B). While NHE1 palmitoylation is decreased with as
low as 1 µM 2BP, change in pHi occurs only in the presence of 10 µM or higher
concentrations of 2BP (Fig. 7A). Taken together, Figure 7 shows 2BP treatment decreases
pHi and suppresses the ability of LPA to increase pHi through NHE1 activity.
Inhibiting Palmitoylation Decreases the Formation of Actin Stress Fibers

The association of stress fibers with the plasma membrane provides critical structural
support for this membrane and the cell as a whole138. Stress fibers are made up of actin
filaments which bind ERM complex proteins (Ezrin, Radixin, Moesin) in order to interact
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with the plasma membrane139,140. NHE1 directly binds Ezrin which also binds actin making
NHE1 a critical anchoring protein for the ERM complex and creating stress fibers
necessary for directed cell migration71. PSN cells display minimal stress fibers in a
quiescent state which can be increased by stimulation of NHE1; specifically LPA has been
shown to increase stress fiber formation through NHE1 activation98. To assess the effect
of palmitoylation on stress fiber formation, cells were treated with vehicle or 15 µM 2BP
for 18 h then stimulated with LPA after which the number of stress fibers present were
counted. As shown in Figure 8, 2BP treatment significantly decreased stress fiber
formation compared to LPA stimulated cells. Surprisingly, 2BP treatment alone
significantly reduced the number of stress fibers compared to control cells. Additionally,
when cells are treated with 2BP prior to stimulation with LPA, stress fiber formation
remained at control levels again demonstrating the ability of 2BP to block LPA stimulation
of NHE1 (Fig. 8) consistent with its ability to inhibit LPA stimulation of NHE1 activity.
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Figure 7 2BP Treatment Decreases Intracellular pH

Figure 7. 2BP Treatment Decreases Intracellular pH. A, pHi after 2BP showing 10
µM and 15 µM 2BP significantly decreased pHi by 0.13 ± 0.04 and 0.25 ± 0.04 pH
units respectively compared to CNT. Quantification performed on at least three
independent experiments performed in duplicate relative to control (CNT) * < p
0.05, ** < p 0.01 **** < p 0.0001 versus CNT (one-way ANOVA Tukey’s post hoc
test, mean ± SD). B, quantification of the change in pHi after LPA treatment (CNT)
shows 2BP significantly abrogates the ability of LPA to activate NHE1. At least three
independent experiments performed in duplicate relative to CNT ** < p 0.01 ***
< p 0.001 versus CNT † < p 0.05 versus 5 µM (one-way ANOVA Tukey’s post hoc
test mean ± SD).
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Figure 8 2BP Attenuates LPA Stimulated Stress Fiber Formation in PSN Cells

Figure 8. 2BP Attenuates LPA Stimulated Stress Fiber Formation in PSN Cells. A,
PSN cells with fluorescently labeled actin stress fibers showing and increase
number of stress fiber containing cells after LPA treatment (29.7 ± 2.7%) and a
decreased number of cells containing stress fibers after 2BP treatment (9.1 ± 2.7%).
Cells pretreated with 2BP then stimulated with LPA had significantly less cells
containing stress fibers compared to LPA alone (33.6 ± 2.7%). B, quantification of
the number of cells containing stress fibers as mean ± SD of four independent
experiments performed in duplicate relative to control (CNT), * < p 0.05, *** < p
0.001 and ††† < p 0.001 versus LPA (one-way ANOVA with Tukey’s post hoc test,
Mean ± SD).
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Inhibition of Palmitoylation Reduces Cell Migration and Proliferation

The role of ion translocation through NHE1 in cell migration is well documented107,141–
143

. NHE1 localizes to the leading edge of the cell resulting in the formation of a pH

gradient within the cell. The alkalization of the leading edge of the cell is important for
the formation of stress fibers which associate directly with NHE1 through ERM binding
and are vital for directed cell migration106,123. Thus both proton transport and stress fiber
formation mediated through NHE1 are critical for directed cell motility in healthy cells144–
146

. As such determining the effect of 2BP treatment on PSN cell migration provides

valuable insight on potential mechanisms of NHE1 regulation by palmitoylation.
As shown in Figure 9, PSN cells were treated with increasing concentrations of 2BP
for 18 h then wound healing assays were performed to measure cell migration and
calculate cell velocity. In reference to the wound healing assay, we found a dose-response
effect to the palmitoylation inhibitor where increasing concentrations of 2BP further
reduced the migration of cells into a vacated wound. After 24 h, cells nearly filled the
entirety of the wound with control cells and cells treated with lower concentrations of
2BP (1 µM and 5 µM). Whereas cells treated with higher concentrations of 2BP (10 µM
and 15 µM) did not display closed wounds even after 28 h. The velocity (µm/min) of cell
migration was examined while PSN cells were in the mid-stage of movement (between 6
h and 12 h, see Methods for calculation). Even the lowest concentration of 2BP (1 µM)
inhibited the cellular rate of travel from 0.64 µm/min (control) to 0.48 µm/min (2BP). We
continued to see decreased cell motility in a concentration-dependent manner with 2BP
treatments as high at 15 µM. Electric cell impedance system (ECIS) is a biophysical
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approach used to dynamically measure cell migration in real time. Using this method, PSN
cells were seeded on the chamber and grown to confluence followed by treatment with
15 µM 2BP. After 18 h, an electric current was applied electroporating the cells resulting
in death of cells only on the electrode thereby creating a defined wound. Cell impedance
was then measured continuously for 7 h as cells migrated toward the electrode. Figure
9D shows that cell impedance over time is reduced when cells are treated with 2BP
compared to control cells. Furthermore, we found 2BP significantly reduced PSN cell
adhesion on collagen, poly L-lysine, or Matrigel™ treated surfaces which was not
observed with PS120 (NHE null) cells (data not shown). This indicates that global inhibition
of palmitoylation by 2BP led to decreased cell attachment, most likely due to loss of NHE1
palmitoylation and associated cellular functions. This could in part, explain the impact of
2BP treatment on cell migration and velocity. Figure 9E shows treatment with 15 µM 2BP
for 18 h significantly decreased PSN cell proliferation stimulated in the presence of
lysophosphatidic acid (LPA). LPA acts as a mitogen to activate NHE198 which increases cell
proliferation, as shown in Figure 9E, while 2BP pretreatment resulted in ablation of LPA
stimulated cell proliferation compared to no pretreatment control demonstrating 2BP
blocks the effect of LPA on cell proliferation. Taken together, this data shows inhibiting
palmitoylation, using 2BP, in PSN cells significantly reduces stress fiber formation leading
to reduced cell migration and proliferation.
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Figure 9 PSN Cell Migration and Proliferation are Hindered by 2BP

Figure 9. PSN Cell Migration and Proliferation are Hindered by 2BP. Cell migration was
evaluated by measuring ability of cells to close the wound over 28 h. A, quantification of
wound closure after increasing concentrations of 2BP. B, representative image of the initial
wound at 0 h with 2BP treatment resulting in reduced would closure after 24h. C,
quantification of average cell velocity using calculated using wound healing data. D,
representative trace of cell migration measured by electric cell impedance sensing showing
15 µM 2BP treatment decreases the ability of cells to migrate over 7 h compared to control
cells. E, Treatment with 15 µM 2BP for 18 hours results in significantly decreased PSN cell
proliferation after 15 min LPA stimulation (10 µM) compared to LPA alone treated and
control cells. Quantifications done as mean ± SD of at least three independent experiments
relative to control (CNT), * < p 0.05, ** < p 0.01, *** < p 0.001 and ††† < p 0.001 versus LPA
(one-way ANOVA with Tukey’s post hoc test, Mean ± S.D).
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Discussion
In this study, we show for the first time that NHE1, a SLC9 transporter, is acylated in
both cells and rat tissues providing a novel mechanism of NHE1 regulation, which is critical
in multiple cellular properties including cellular pH, stress fiber formation, migration, and
proliferation. Using the PAT inhibitor, 2BP, we showed NHE1 acylation decreases in a
time-dependent manner consistent with the irreversible nature of the inhibitor (Fig. 6A),
and using metabolic labeling we identified the incorporation of [3H]palmitate into NHE1
confirming palmitoylation of NHE1 also demonstrated using the ABE method (Fig. 4).
NHE1 was fairly sensitive to 2BP treatments with decreases in NHE1 palmitoylation seen
within 30 min of exposure to 1 µM 2BP which continued through 18 h in a stepwise
manner (Fig. 6A). Loss of NHE1 palmitoylation plateaued after 18h of treatment with 1
µM 2BP as increasing the concentration did not result in increased loss of NHE1
palmitoylation Fig. 6B).
Prior to assessing the effect of 2BP and loss of palmitoylation on NHE1 function we
established that 2BP had no effect on the viability NHE1 expressing PSN cells or the nonNHE1 expressing parent line (PS120) in the 18h time frame and 2BP concentrations used
in our experiments (Fig. 5). This assured that any NHE1 functional effects seen in the
presence of 2BP would not be attributable to cell viability but to the loss of palmitoylation.
Since loss of palmitoylation can affect protein turnover147 we utilized 2BP concentrations
(1-15 µM) and an 18 h incubation period where no loss of total cellular NHE1 was detected
(see Fig. 6) assuring that changes NHE1 functional effects would not be attributable to
loss of NHE1 itself.
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With this in mind, we found that 2BP treatments led to decreased NHE1
palmitoylation and altered cellular properties associated with NHE1 including cellular pH,
stress fiber formation, migration, and proliferation. We found a concentration dependent
decrease in intracellular pH in response to inhibition of palmitoylation by 2BP. However,
there was not a close correlation between loss of NHE1 palmitoylation and decreased pHi
where 1-15 µM 2BP treatments led to equivalent loss of NHE1 palmitoylation while 1 µM
2BP had no effect on pHi and 10-15 µM 2BP significantly decreased pHi (Fig. 7A). This
result suggests that palmitoylation of NHE1 may not directly influence NHE1 transport
capacity, however, this remains to be explored because NHE1 transport is dependent on
cell surface levels of the exchanger in addition to intrinsic exchanger kinetics. The cell
surface transport capacity of NHE1 may be sufficient to maintain cellular pH in the
presence of lower concentrations of 2BP but not with higher concentrations suggesting
that binding partner interactions and their palmitoylation status may be relevant in
maintaining cellular pH via NHE1 activity.
To begin assessing the effect of NHE1 palmitoylation on NHE1-associated cellular
functions, we measured the effect of 2BP on pHi after stimulation with LPA. LPA is a wellknown agonist of NHE1 increasing activity and thus increasing pHi98. When cells are first
treated with 2BP then challenged with LPA we found a reduced ability of LPA to stimulate
NHE1 activity (Fig. 7B). This indicates LPA plays a role in regulation of NHE1 activity in a
palmitoylation driven manner that is 2BP concentration dependent. This effect is
consistent with the 2BP-dependent loss of LPA-stimulated cell proliferation another well-
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known NHE1-dependent function that is absent in the presence of 2BP suggesting NHE1
palmitoylation is necessary for LPA stimulation cell proliferation and increased pHi.
NHE1 also facilitates protein-protein interactions which regulate stress fiber
formation through interactions with the cytoskeleton, specifically the ERM complex70,148.
PSN cells that that express human NHE1 show reduced stress fiber formation when
treated with 2BP (Fig. 8). In addition, LPA stimulates stress fiber formation and incubation
of PSN cells with 2BP abolished LPA-induced stress fiber formation consistent with 2BP
effects seen with cell proliferation and pHi. The formation of stress fibers in combination
with increased cellular pH, regulated through NHE1 activity and localization, is critical for
directed cell migration143,149. We show in Figure 9 that 2BP treatment also decreases PSN
cell migration demonstrated by reduced wound healing even at the lowest concentration
of 2BP (1 µM) and further thwarts wound closure as 2BP concentration increases.
Additionally, cell velocity is hindered by 2BP in a manner similar to migration with velocity
decreasing in a stepwise manner relative to 2BP concentration. Subsequently, this
provides preliminary evidence that palmitoylation regulates cell migration and stress fiber
formation through a NHE1 mediated mechanism. This suggests that palmitoylation plays
a large role in regulation of the NHE1 and of the multiple vital cellular processes
associated with the exchanger.
The nature of palmitoylation is similar to that of phosphorylation as both
modifications regulate proteins in a rapid and dynamic manner and are themselves
regulated by enzymes which are influenced various external and internal factors. Multiple
studies have shown palmitoylation and phosphorylation occurring on the same proteins
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and working in a reciprocal manner to regulate various protein functions125,150.
Phosphorylation regulates multiple NHE1 functions including activity, stress fiber
formation, cell migration, and cell proliferation all of which are also regulated by
palmitoylation. This suggests NHE1 regulation by palmitoylation may work in concert with
phosphorylation to regulate these critical cellular functions. The initial characterization of
the effects of 2BP on NHE1 mediated cellular processes provided in this study establishes
an important role for palmitoylation in regulating NHE1 and NHE1 mediated cellular
processes. Multiple studies including the identification of NHE1 palmitoylation sites and
the PATs that catalyze the modification of these sites are necessary to fully understand
the effect of NHE1 palmitoylation on cellular processes and diseases related to NHE1.
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Chapter III
PHOSPHORYLATION AND PALMITOYLATION OF THE SODIUM
HYDROGEN EXCHANGER ISOFORM 1 (NHE1)
Abstract
The sodium hydrogen exchanger isoform 1 (NHE1) is a ubiquitously expressed
transmembrane protein that regulates pH and plays a vital role in multiple cellular
processes. Additionally, NHE1 is a scaffolding protein that organizes protein complexes to
regulate various signaling pathways within the cell. Therefore, it is important to
understand the factors contributing to NHE1 regulation as maintenance of these critical
cellular functions is vital to ensure a healthy cell. Phosphorylation and palmitoylation are
both dynamic reversible posttranslational modifications (PTMs) that regulate proteins to
influence critical cellular processes. Previous work in our lab has shown NHE1 is regulated
by palmitoylation and that inhibition of palmitoylation in cells expressing NHE1 decreases
NHE1 activity, as well as NHE1 associated cellular functions such as stress fiber formation
and cell migration. NHE1 is also regulated by phosphorylation of multiple sites through
various kinase pathways. To better understand the relationship between palmitoylation
and phosphorylation on NHE1 we used various stimuli known to regulate multiple kinase
pathways that control NHE1 phosphorylation and measured the impact on NHE1
palmitoylation. Using serum, lysophosphatidic acid (LPA) and phorbol 12-myristate (PMA)
to stimulate NHE1 phosphorylation led to increased palmitoylation of NHE1, while
activation of the NHE1 phosphorylation with insulin led to decreased NHE1
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palmitoylation. Additionally, we found that inhibition of PI3K, AKT, Rsk, and ROCK kinases
all increased NHE1 palmitoylation, while inhibition of ERK1/2 decreased NHE1
palmitoylation. Using this information, we have begun to understand how the presence
or absence of palmitoylation and phosphorylation in a coordinated manner contributes
to a barcode that dictates a regulatory outcome and cellular response involving the
sodium hydrogen exchanger isoform 1 (NHE1).

Introduction
The sodium hydrogen exchanger isoform 1 (NHE1) is a ubiquitously expressed
transmembrane protein that regulates pH by exchanging an intracellular proton for an
extracellular sodium ion75. NHE1 also plays a vital role in multiple cellular processes in
addition to regulating pH such as cellular migration and proliferation, control of cell
volume, and stress fiber formation121,122. Additionally, NHE1 is a scaffolding protein that
organizes protein complexes to regulate various signaling pathways within the cell123,124.
Therefore, it is important to understand the factors contributing to NHE1 regulation and
its role in maintaining critical cellular functions vital to cell health. Regulation of NHE1
occurs on the large intracellular C-terminus where binding partners and posttranslational
modifications (PTMs) influence the exchanger in both short- and long-term manners.
Major binding partners include PIP2100 and ERM71 which are important for association of
the tail to the inner membrane leaflet and the formation of stress fibers, respectively123.
Ca2+/calmodulin binding sites also on the C-terminal tail have been shown to play an
important role in proton affinity and thus regulate NHE1 activity107. Additionally, multiple
phosphorylation sites are also present on the C-terminus which have varying effects on

56

NHE1 activity and the multiple cellular processes in which NHE1 plays a role. Together
these many regulatory factors control NHE1 activity, localization, and expression, all of
which are important for regulation of critical cellular processes.
Phosphorylation and palmitoylation are both dynamic reversible posttranslational
modifications (PTMs) that regulate proteins through which many critical cellular
processes are influenced. Multiple studies have shown phosphorylation and
palmitoylation can work together in a barcode to regulate proteins and alter cellular
functions125,150–153. Phosphorylation is the reversible addition of a phosphoryl group from
adenosine triphosphate (ATP) to primarily serine, threonine, or tyrosine residue and is
broadly considered the most common posttranslational modification2,8. Phosphorylation
introduces a charged phosphate group which induces an altered conformational change
that can affect catalytic activity of proteins, the tendency of proteins to aggregate, and
the ability to recruit binding partners, all of which result in altered protein function and
cell signaling2,5. S-Palmitoylation is the addition of a 16-carbon fatty acid to a cysteine
residue via a thioester bond. Palmitoylation is a unique lipid modification as it is
reversible, with palmitoyl acyltransferases (PATs) catalyzing the addition of palmitate
while acyl protein thioesterases (APTs) and palmitoyl-protein thioesterases (PPTs)
catalyzing the removal of palmitate via a thioester bond at intracellularly available
cysteine residues. The most well studied function of palmitoylation is trafficking of
proteins between the organelles and increasing membrane association of cytosolic
proteins. Recent studies have demonstrated that palmitoylation has multiple other
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effects on proteins, particularly transmembrane proteins where effects include regulation
of protein activity, membrane microlocalization and protein-protein interactions125,126.
Previous work in our lab has shown NHE1 is regulated by palmitoylation and that
inhibition of palmitoylation in cells expressing NHE1 decreases intracellular pH, which is
associated with NHE1, as well as NHE1 associated cellular functions such as stress fiber
formation and cell migration (Chapter II). Many binding partners and kinases interact
directly or indirectly to regulate NHE1 activity. Identifying and understanding how these
complex pathways are coordinated resulting in NHE1 regulation is on-going. Various
growth factors and hormones stimulate NHE1 phosphorylation including thrombin,
serum, epidermal growth factor, insulin, angiotensin II, phorbol esters, and
lysophosphatidic acid (LPA). Figure 10 shows diagrams a few of the pathways that lead to
NHE1 phosphorylation. We hypothesize these same growth factors, that stimulate NHE1
phosphorylation, will also alter NHE1 palmitoylation. To address this hypothesis, we
stimulated NHE1 using serum, insulin, LPA, and phorbol 12-myristate (PMA). Serum, LPA,
and PMA all increased NHE1 phosphorylation as well as palmitoylation. Conversely,
stimulation of NHE1 phosphorylation with insulin led to decreased NHE1 palmitoylation.
Additionally, we inhibited several kinases that directly and indirectly lead to NHE1
phosphorylation, to aid in understanding how different phosphorylation pathways
participate in regulation of NHE1 by palmitoylation. This information has allowed us to
begin understanding how the presence or absence of palmitoylation and phosphorylation
in a coordinated manner contributes to a barcode that dictates a regulatory outcome and
cellular response involving the NHE1.
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Figure 10 Pathways Involved in the Phosphorylation of NHE1

Figure 10. Pathways Involved in the Phosphorylation of NHE1. Diagram of the
multiple pathways involved in NHE1 phosphorylation. Stimuli can activate one or more
of these pathways initiating kinase cascades resulting in the phosphorylation of NHE1
at various residues.
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Materials
Colorburst molecular mass standard, 2- bromopalmitate (2BP), and mouse anti-flag tag
antibody were from Sigma Millapore and anti-NHE1(54) mouse monoclonal antibody (sc136239) was from Santa Cruz Biotechnology. High capacity NeutrAvidin ®-agarose resin,
and bicinchoninic acid protein (BCA) assay reagent were from Thermo Scientific. HPDPbiotin

was

from

APExBio,

BCECF-AM

2ʹ,7ʹ-bis-(carboxyethyl)-5-(and-6)-

carboxyfluorescein was from Molecular Probes and Nigericin was from Tocris Bioscience.
LPA in the form of 14:0 1-myristoyl-2-hydroxy-sn-glycero-3phosphate (sodium salt) was
from Avanti Polar Lipids. LY294002, PD98059, BID-1870, Y27632, AKT1X were from Adooq
Biosciences. Human insulin was from Alfa Aesar and PMA was from Sigma Millapore.

Methods
Cell Culture

NHE1-null cells (PS120 cells, a gift from D. Barber, University of California, San
Francisco) derived from Chinese hamster lung fibroblasts CCL339 were used to generate
a cell line stably expressing human NHE1 with an HA DDK epitope tag on the C terminus
(PSN cells). These cells were maintained in Dulbecco’s modified Eagle medium (DMEM)
supplemented with 20% fetal bovine serum, 2 mM L-glutamine, and 200 µg/ml G418 at
37oC in a humidified 5% CO2 incubator after clonal isolation 98.
Cell Treatments and Membrane Preparation for Palmitoylation Detection

PSN cells were subcultured, seeded on 150 mm culture dishes, and grown to
confluency followed by treatment with experimental conditions as described. After
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treatments, cells were washed twice with 3 mL of ice-cold buffer B (0.25 M sucrose, 10
mM triethanolamine, 10 mM acetic acid, pH 7.8) and then scraped to one side of the plate
using 0.5 mL of buffer B and transferred to a 2 mL microcentrifuge tube on ice. Cells were
then pelleted by centrifugation at 3,000 x g for 5 min at 4oC. The supernatant fraction was
removed and 1 mL of ice-cold buffer C (0.25 M sucrose, 10 mM triethanolamine, 10 mM
acetic acid, 1 mM EDTA, pH 7.8) containing protease inhibitors was added to break the
pellet loose. The solution containing the loose pellet was then homogenized in a Dounce
homogenizer with 30 up and down strokes on ice. The resulting homogenate was
centrifuged at 800 x g for 10 min at 4°C to pellet and remove nuclei and cell debris. The
supernatant fraction was transferred to a new tube which was centrifuged at 16,000 x g
for 12 min at 4°C to precipitate cell membranes. The supernatant fraction was removed
and the pellet containing cell membranes was resuspended in 1 mL sucrose-phosphate
(SP) buffer (10 mM sodium phosphate, 0.32M sucrose, pH 7.4) and assayed for protein
content.
Palmitoylation Detection using Acyl-Biotinyl Exchange (ABE)

Adapted from Wan et al134 palmitoylated proteins are detected using three steps.
(i) Free cysteine thiols are blocked; membranes isolated from PSN cells were solubilized
in lysis buffer (50 mM HEPES pH 7.0, 2% SDS (w/v), 1 mM EDTA) containing protease
inhibitors and 25 mM N-ethylmaleimide (NEM) and incubated for 20 minutes at 37oC,
followed by acetone precipitation. Precipitated proteins were again solubilized in lysis
buffer containing protease inhibitors and NEM and incubated at room temperature with
end over end mixing overnight. NEM was removed by three consecutive acetone
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precipitations in which the protein pellet was resuspended in 4SB buffer (4% SDS, 50 mM
Tris, 5 mM EDTA, pH 7.4) followed by acetone precipitation. (ii) Thioester linked palmitoyl
groups are specifically removed using hydroxylamine (HAM); The resuspended protein
sample is split equally into negative control (50 mM Tris-treated) and HAM-treated (0.7
mM) halves and incubated at room temperature for 15 min with end-over-end mixing.
(iii) The previously palmitoylated and now free sulfhydryl groups are then biotinylated by
the addition of sulfhydryl specific HPDP-biotin (0.4 mM, 50 mM Tris-HCl, pH 7.4) for 1 h
at room temperature with end over end mixing, HAM and unbound biotin was removed
with three sequential acetone precipitations; the biotinylated proteins were then affinity
purified using NeutrAvidin® resin. Bound proteins were eluted, subjected to SDS-PAGE,
and immunoblotted with mouse anti-Flag M2 primary antibody to detect tagged NHE1.

Results
Serum Stimulation Increases NHE1 Palmitoylation

To study the influence of growth factors on NHE1 palmitoylation we began by
looking at low serum (0.5%) and high serum (20%) conditions. Previous studies have
shown that serum stimulates NHE1 phosphorylation through ERK signaling with Rsk
kinase directly phosphorylating NHE1 at S703 in fibroblast cells111,154. PSN cells were
plated, allowed to attach and after 18 h the media was replaced with media containing
either 20% or 0.5% serum. After an additional 24 h incubation, membranes we prepared
and NHE1 palmitoylation was analyzed using the ABE method. Figure 11 shows serum
stimulated NHE1 is 25 ± 8.8 % more palmitoylated than when serum starved.
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Lysophosphatidic Acid (LPA) Increases NHE1 Palmitoylation

LPA, a component found in serum, acts as a mitogen signaling through G-protein
coupled receptors activating growth factor pathways via Ras-ERK. Previous studies have
shown LPA stimulates NHE1 phosphorylation by RhoA/ROCK and ERK/Rsk pathways98. In
Figure 12 we show LPA stimulation increase NHE1 palmitoylation after 10 min by 79.7 ±
16.5 % compared to no treatment. This continues in a time dependent manner with LPA
stimulation increasing NHE1 palmitoylation 133.1 ± 18.8 % after 15 min. Moreover, when
cells are treated with 2BP, an inhibitor of palmitoylation, for 30 min prior to LPA
stimulation the ability of LPA to increase NHE1 palmitoylation is diminished. As both NHE1
phosphorylation and palmitoylation are increased by LPA they may work in a cooperative
manner to integrate the LPA stimulated pathway regulating NHE1 activity and function.
Figure 13 shows both 5 and 15 µM 2BP plus LPA treatment decreased NHE1
palmitoylation by 62.0 ± 9.5% and 50.6 ± 8.3 % versus LPA alone respectively. Showing
2BP can abrogate the effect of LPA on NHE1 is consistent with previous data (Chapter II similar effects as those shown in Figure 8 with respect to pHi).
Insulin Decreases NHE1 Palmitoylation

Insulin, another growth factor, signals through the insulin receptor to activate the
PI3K/AKT phosphorylation pathway. Barber et al 2009 showed AKT phosphorylates NHE1
at residue S648 to modulate stress fiber formation through NHE1 phosphorylation70. Here
we show stimulation of cells for 10 min with 100 nM insulin decreased NHE1
palmitoylation by 38.0 ± 5.7 % (Figure 14). Insulin treatment is known to increase NHE1
phosphorylation and here we show the same stimulation decreases NHE1 palmitoylation.
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This indicates that palmitoylation and phosphorylation may work in a reciprocal manner
to regulate NHE1.
PMA Increases NHE1 Palmitoylation

PMA (Phorbol 12-myristate 13-acetate) is a phorbol ester (PE) that binds and activates
PKC. Multiple studies about the effects of PEs, including PMA, have shown PEs are critical
for regulating the lipid-interacting domain (LID) of NHE1118,155. Some studies have also
shown treatment with PEs increases NHE1 phosphorylation however, no direct PKC
phosphorylation site has been found on NHE169. In Figure 15 we show treatment of cells
with 10 µM PMA increases NHE1 palmitoylation by 23.5 ± 5.0 % after 20 min of exposure.
PMA treatment promotes the interaction of the LID region of NHE1 with the
membrane118. Here we show PMA stimulation also increases NHE1 palmitoylation
indicating palmitoylation could play a critical role in the association of NHE1 with the
membrane, specifically in the LID region which contains cysteine residue 561 which could
be a potential palmitoylation site.
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Figure 11 NHE1 is More Palmitoylated in High Serum Conditions

Figure 11. NHE1 is More Palmitoylated in High Serum Conditions.
A. Western blot representative of at least three independent
experiments showing increased palmitoylation after 24 h serum
stimulation as total NHE1 levels remain the same. B.
Quantification of NHE1 palmitoylation (mean ± S.E. of at least
three independent experiments relative to 0.5% Serum) * p < 0.05
versus 0.5% Serum (Student’s t-test).
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Figure 12 LPA Increases NHE1 Palmitoylation

Figure 12. LPA Increases NHE1 Palmitoylation A. Western blot
representative of at least three independent experiments for each
treatment showing palmitoylated NHE1 increasing in a time
dependent manner following LPA treatment as total NHE1 levels
remain the same B. Quantification of NHE1 palmitoylation
normalized to total NHE1 present (mean ± S.E. of at least three
independent experiments relative to control (NT) normalized to
100%.) ** p < 0.01 and **** p < 0.0001 versus NT and † p < 0.05
versus 10 min (one-way ANOVA with Tukey’s post hoc test).
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Figure 13 The Effect of LPA and 2BP Treatment on NHE1 Palmitoylation

5 µM 2BP

15 µM 2BP

Figure 13. The Effect of LPA and 2BP Treatment on NHE1 Palmitoylation. A/C.
Western blot representative of at least three independent experiments for each
treatment showing 5 and 15 µM 2BP decrease NHE1 palmitoylation, LPA increase
NHE1 palmitoylation and pretreatment with 2BP abrogates the ability of LPA to
stimulate NHE1 palmitoylation. B/D. Quantification of NHE1 palmitoylation
normalized to total NHE1 (mean ± S.E. of at least three independent experiments
relative to vehicle (NT) normalized to 100%.) * p < 0.05, ** p < 0.01, *** p < 0.001
versus NT, † p < 0.05, ††† p < 0.001 versus LPA (one-way ANOVA with Tukey’s post
hoc test).
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Figure 14 Insulin Decreases NHE1 Palmitoylation

Figure 14. Insulin Decreases NHE1 Palmitoylation A. Western blot
representative of at least three independent experiments
showing NHE1 palmitoylation decreases after insulin treatment
with total NHE1 levels remaining the same. B. Quantification of
palmitoylated NHE1 normalized to total NHE1 (mean ± S.E. of at
least three independent experiments relative to control (NT)
normalized to 100%.) *** p < 0.001 versus NT (Student’s t-test).
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Figure 15 PMA Increases NHE1 Palmitoylation

Figure 15. PMA Increases NHE1 Palmitoylation. A. Western blot
representative of at least three independent experiments
showing NHE1 palmitoylation decreases after PMA treatment
with total NHE1 levels remaining the same. B. Quantification of
palmitoylated NHE1 normalized to total NHE1 (mean ± S.E. of at
least three independent experiments relative to control (NT)
normalized to 100%.) *** p < 0.001 versus NT and ††† p < 0.001
versus 10 min (one-way ANOVA with Tukey’s post hoc test).
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PI3K and AKT Inhibition Increases NHE1 Palmitoylation

Insulin signals through the PI3K/AKT pathway leading to increased NHE1
phosphorylation at S64870. To begin assessing the involvement of kinases downstream of
insulin binding to its receptor in regulating NHE1 palmitoylation we used LY294002 or
AKTX1 to inhibit PI3K or AKT respectively. In Figure 16 we show NHE1 palmitoylation
increases 37.0 ± 9.8% after treatment with 10 µM LY294002 for 20 min consistent with
insulin pathway stimulation decreasing NHE1 palmitoylation. Additionally, treatment
with 10 µM AKTX1 for 1 h increased NHE1 palmitoylation by 69.6 ± 5.9 % (Fig. 17). This
aligns with the previous data showing insulin treatment decreases NHE1 palmitoylation,
implicating the PI3K/AKT pathway as a major player linking NHE1 palmitoylation and
phosphorylation.
MEK Inhibition Decreases NHE1 Palmitoylation

To further explore the role of phosphorylation on NHE1 palmitoylation we used
PD98059 to inhibit MEK activity while cells were maintained in 20 % serum. Cells were
treated with 10 µM PD98059 for the indicated time and NHE1 palmitoylation was
measure using the ABE detection method. We found NHE1 palmitoylation was decreased
by 46.6 ± 5.0 % compared to no treatment after 20 min of inhibition and was maintained
at 30 min of treatment (Fig. 18). The MEK/ERK/Rsk kinase pathway is involved in direct
phosphorylation of NHE1 at S770/77178. Here we show inhibition of ERK results in
decreased palmitoylation which aligns with our earlier data showing the presence of
serum promotes NHE1 palmitoylation. Decreased NHE1 palmitoylation after MEK
inhibition is consistent with data in Figure 9 showing serum stimulates NHE1
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palmitoylation linking MEK activity and NHE1 phosphorylation at S770/771 to regulation
of NHE1 palmitoylation.
Rsk and ROCK Inhibition Increases NHE1 Palmitoylation

Another kinase pathway involved in the activation of NHE1 by phosphorylation is
the ERK/Rsk/ROCK pathway. BI-D1870 is a selective Rsk inhibitor that has been used
extensively in previous studies to decrease NHE1 phosphorylation at S703 after serum
stimulation156. In Figure 19 we show cells treated with 10 µM BI-D1870 for 30 min have a
40.6 ± 6.4 % increase in NHE1 palmitoylation. Likewise, NHE1 is directly phosphorylated
by ROCK at T65398 and when cells are treated with 10 µM of ROCK inhibitor Y-27632 for
30 min NHE1 palmitoylation is increased by 52.3 ± 17.3 % (Fig. 20). This increase in NHE1
palmitoylation after both ROCK and Rsk inhibition suggests stimuli increasing
phosphorylation at S703 and T653 have an opposite effect on NHE1 palmitoylation than
stimulus that increase phosphorylation at the ERK specific site S770/771.
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Figure 16 Inhibition of PI3K Increases NHE1 Palmitoylation

Figure 16. Inhibition of PI3K Increases NHE1 Palmitoylation. A.
Western blot representative of at least three independent
experiments showing NHE1 palmitoylation decreases after
inhibition of PI3K with LY29400 treatment with total NHE1 levels
remaining the same. B. Quantification of palmitoylated NHE1
normalized to total NHE1 (mean ± S.E. of at least three
independent experiments relative to vehicle (NT) normalized to
100%.) * p < 0.05 versus NT and † p < 0.05 versus 10 min (one-way
ANOVA with Tukey’s post hoc test).
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Figure 17 Inhibition of AKT Increases NHE1 Palmitoylation

Figure 17. Inhibition of AKT Increases NHE1 Palmitoylation. A.
Western blot representative of at least three independent
experiments showing NHE1 palmitoylation decreases after
inhibition of AKT with AKT1X treatment with total NHE1 levels
remaining the same. B. Quantification of palmitoylated NHE1
normalized to total NHE1 (mean ± S.E. of at least three
independent experiments relative to vehicle (NT) normalized to
100%.) *** p < 0.001 versus NT and ††† p < 0.001 versus 20 min
(one-way ANOVA with Tukey’s post hoc test).
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Figure 18 Inhibition of MEK Decreases NHE1 Palmitoylation

Figure 18. Inhibition of MEK Decreases NHE1 Palmitoylation. A.
Western blot representative of at least three independent
experiments showing NHE1 palmitoylation decreases after
inhibition of MEK with PD98059 treatment with total NHE1 levels
remaining the same. B. Quantification of palmitoylated NHE1
normalized to total NHE1 (mean ± S.E. of at least three
independent experiments relative to control (NT) normalized to
100%.) *** p < 0.001 versus NT (one-way ANOVA with Tukey’s
post hoc test).
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Figure 19 Inhibition of Rsk Increases NHE1 Palmitoylation

Figure 19. Inhibition of Rsk Increases NHE1 Palmitoylation. A.
Western blot representative of at least three independent
experiments showing NHE1 palmitoylation decreases after
inhibition of Rsk with BI-D1870 treatment with total NHE1 levels
remaining the same. B. Quantification of palmitoylated NHE1
normalized to total NHE1 (mean ± S.E. of at least three
independent experiments relative to control (NT) normalized to
100%.) ** p < 0.01 versus NT (one-way ANOVA with Tukey’s post
hoc test).
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Figure 20 ROCK Inhibition Increases NHE1 Palmitoylation

Figure 20. ROCK inhibition increases NHE1 palmitoylation. A.
Western blot representative of at least three independent
experiments showing NHE1 palmitoylation decreases after
inhibition of ROCK with Y-27632 treatment with total NHE1 levels
remaining the same. B. Quantification of palmitoylated NHE1
normalized to total NHE1 (mean ± S.E. of at least three
independent experiments relative to control (NT) normalized to
100%.) ** p < 0.01 versus NT (one-way ANOVA with Tukey’s post
hoc test).
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Discussion
NHE1 has a large number of phosphorylation sites that work together to regulate
NHE1 activity, localization, and protein-protein interactions. All of these factors are
important for maintaining cellular pHi as well as keeping cells in a homeostatic state. Our
previous work has shown that in addition to phosphorylation NHE1 is also palmitoylated,
a reversible lipid modification, that we now have linked to regulation of multiple NHE1
associated functions (Figs. 7-9). Cell growth is regulated, in part, by pHi and stimulated by
various growth factors and hormones. Extensive research has been done looking at the
role of growth factors, hormones, and cell signaling molecules on NHE1 regulation with a
focus on the specific phosphorylation pathways and kinases involved in NHE1
phosphorylation72,77,78,98,117,120,155,157. Multiple studies have shown a link between
phosphorylation and palmitoylation working to regulate the same protein in either a
reciprocal or cooperative manner125,150,158–161. Here we show serum, LPA, and PMA, all
factors that increase NHE1 phosphorylation at distinct sites, increase NHE1 palmitoylation
and insulin, also known to specifically increase NHE1 phosphorylation, decreases NHE1
palmitoylation. We then inhibited several kinases directly involved in NHE1
phosphorylation and examined the effect on NHE1 palmitoylation, which is described
below.
Serum contains a number of growth factor that can activate the cell and stimulate
NHE1 activity through phosphorylation of S703 and enhance 14-3-3 binding to NHE1.
Figure 11 shows NHE1 is more palmitoylated in the presence of high serum. Accordingly,
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palmitoylation of NHE1 might contribute to NHE1 being in a more active state in response
to serum.
LPA, a component of serum, acts as a mitogen to signal through GPCRs to activate
MAPK cascades. LPA activation of ERK results in direct phosphorylation of NHE1 at
residues S770/771. LPA treatment increases NHE1 palmitoylation within 10 min and this
increase continues in a time-dependent manner (Fig. 12). While LPA signals through
multiple pathways leading to the possibility that many factors may be contributing to the
increase in NHE1 palmitoylation here we show that LPA stimulates NHE1 palmitoylation
and phosphorylation suggesting these modifications may work in a cooperative manner
to regulate NHE1. Insulin signaling occurs through the PI3K/AKT phosphorylation pathway
to phosphorylate NHE1 at S648. In Figure 14 we show cells treated with 100 nM insulin
have decreased NHE1 palmitoylation after 10 min. This implies the AKT phosphorylation
pathway results in a reciprocal relationship between NHE1 phosphorylation and
palmitoylation.
Phorbol esters such as PMA activate PKC signaling pathways. While no PKC
phosphorylation site has been established on NHE, studies have found a defined role for
PMA activation of NHE1. A defined binding motif for phorbol esters on NHE1 shows PMA
acts in a PKC independent manner to activate NHE1 by increased association of the lipid
interacting domain (LID) on NHE1 with the membrane118. In Figure 15 we show PMA
modestly increases NHE1 palmitoylation suggesting a potential role for palmitoylation
facilitating LID membrane interaction through a PKC mediated mechanism. A potential
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NHE1 palmitoylation site is located within the LID area at residue C561 supporting this
theory.
Taken together we show various stimuli that signal through different kinase
pathways and contribute to NHE1 palmitoylation in both cooperative and reciprocal
manners. To continue exploring this connection between NHE1 phosphorylation and
palmitoylation we used specific kinase inhibitors to inhibit specific signaling pathways and
measured the effect on NHE1 palmitoylation.
First looking at the insulin stimulated PI3K/AKT phosphorylation pathway we show
inhibition of PI3K or AKT results in increased NHE1 palmitoylation (Figs. 16 and 17
respectively). This is consistent with and supportive of results in Figure 14 showing insulin
treatment decreases NHE1 palmitoylation. AKT is responsible for phosphorylation of
NHE1 at S648 where stimulation of this pathway using insulin increases NHE1
phosphorylation at S64870 and decreases NHE1 palmitoylation implying palmitoylation
and phosphorylation may work to regulate NHE1 in a reciprocal manner. The ERM protein
complex binds NHE1 between residues 550-566 which facilitates the formation of stress
fibers. Phosphorylation of S648 on NHE1 through AKT reduces the presence of actin stress
fibers by encouraging depolymerization. As shown previously in Figure 8, inhibition of
palmitoylation using 2BP results in decreased formation of stress fibers and here we show
treatment of cells with insulin which promotes S648 phosphorylation leading to
depolymerization of stress fibers, decreases NHE1 palmitoylation (Figure 14). The ERM
binding domain is located between residues 550-566, a potential palmitoylation site at
residue C561 could offer an explanation for this relationship. Palmitoylation of NHE1
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decreases stress fiber formation which could be due to the palmitate inhibiting ERM
binding either sterically or by embedding the ERM binding motif into the membrane thus
preventing the formation of stress fibers.
LPA

activates

MEK/ERK

phosphorylation

pathway

resulting

in

NHE1

phosphorylation at S770/771. Inhibition of MEK using PD98059 decreases NHE1
palmitoylation (Fig. 18) which aligns with LPA increasing NHE1 palmitoylation (Fig. 12).
Phosphorylation of NHE1 S770/771 sites increases NHE1 activity in response to sustained
acidosis. Figure 16 along with previous data showing inhibition of palmitoylation result in
a more acidic pHi (Fig. 7) provides preliminary evidence that palmitoylation may play a
role in cooperating with phosphorylation at these specific sites to increase NHE1 activity.
Serum contains many growth factors and has been shown to activate the
ERK/Rsk/ROCK pathway to phosphorylate NHE1. Rsk phosphorylates NHE1 at S703
creating a binding pocket for 14-3-3 protein binding, which when bound decreases the
rate of S703 dephosphorylation. Binding of 14-3-3 to NHE1 is necessary for serum
activation of NHE1. In conjunction with serum increasing NHE1 palmitoylation (Fig. 11)
ERK inhibition decreases NHE1 palmitoylation (Fig. 18). Interestingly when Rsk, the next
step in the ERK pathway and kinase that directly phosphorylates S703, is inhibited NHE1
palmitoylation increases (Fig. 19). Additionally, serum promotes phosphorylation of NHE1
at T653 through ROCK, which when inhibited results in increased NHE1 palmitoylation
(Fig. 20). While this seems contradictory it is likely due to the complexity of growth factor
pathways influencing NHE1. Overall this data provides preliminary evidence that
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palmitoylation and phosphorylation work to create specific barcoding patterns that
dictate a regulatory outcome and cellular response involving NHE1.
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CHAPTER IV
DISCUSSION
Here we show for the first time NHE1, a SLC6A transporter, is acylated in both
cells and rat tissue providing a novel mechanism of NHE1 regulation. Using the PAT
inhibitor, 2BP, we showed NHE1 acylation decreases in a time dependent manner. While
2BP globally inhibits palmitoylating enzymes (PATs) we show treatment of PSN cells with
2BP in the time and concentration range which decreases NHE1 palmitoylation also alters
multiple cellular properties associated with NHE1 including cellular pH, stress fiber
formation, migration, and proliferation. We determined the concentration range in which
2BP treatment decreases NHE1 palmitoylation without causing a loss in total NHE1
protein levels begins at a concentration of 1 µM 2BP and continues until 15 µM 2BP.
Additionally, we begin to see decreased NHE1 palmitoylation within 30 min at even the
lowest concentration (1 µM) of 2BP which continues through 18 h in a stepwise manner.
This provides a range of 2BP concentration and times which are effective in reducing
NHE1 palmitoylation without significantly effecting total NHE1 levels or cell viability which
we subsequently used to examine the effect of decreased palmitoylation on cell
physiology attributed to NHE1 function and can continue to be used in future
experiments.
We then used these concentrations and treatment times to establish 2BP
decreases pHi which is associated with decreased NHE1 activity. To begin teasing out
specific stimuli that have a greater effect on NHE1 palmitoylation we measured the effect
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of 2BP on pHi after stimulation with LPA. LPA is a well-known agonist of NHE1 increasing
activity and thus increases pHi98. When cells are first treated with 2BP and then challenged
with LPA we found a reduced ability of LPA to stimulate NHE1 activity. This indicates LPA
plays a greater role in regulation of NHE1 activity in a palmitoylation driven manner than
serum.
NHE1 also facilitates protein-protein interactions which regulates stress fiber
formation through interactions with the cytoskeleton, specifically the ERM complex70,148.
PSN cells treated with 2BP show reduced stress fiber formation and again when PSN cells
were treated with 2BP, the ability of LPA to increase stress fiber formation was abolished
as seen with pHi effects. Additionally, 2BP treatment decreases PSN cell migration shown
by reduced wound healing, decreased cell velocity and decreased cell impendence. This
suggests that palmitoylation plays a large role in regulation of the NHE1 and of the
multiple vital cellular processes associated with the exchanger.
The initial characterization of the effects of 2BP on NHE1 mediated cellular
processes provided in this study establishes an important role for palmitoylation in
regulating NHE1 and NHE1 mediated cellular processes. The nature of palmitoylation is
similar to that of phosphorylation as both modifications regulate proteins in a rapid and
dynamic manner and are themselves regulated by enzymes which are influenced various
external and internal factors. Multiple studies have shown palmitoylation and
phosphorylation occurring on the same proteins and working in a reciprocal manner to
regulate various protein functions125,150.
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NHE1 has a large number of phosphorylation sites all of which work together to
regulate NHE1 activity, localization, and protein-protein interactions. All of these factors
are important for maintaining cellular pHi as well as keeping cells in a homeostatic state.
Various growth factors and hormones stimulate NHE1 phosphorylation. Here we show
serum, LPA, and PMA, all factors that increase NHE1 phosphorylation, increase NHE1
palmitoylation and insulin, also known to increase NHE1 phosphorylation, decreases
NHE1 palmitoylation. We then inhibited several kinases directly involved in NHE1
phosphorylation and examined the effect on NHE1 palmitoylation which effects cell
physiology.
High serum levels and the growth factors within activate the cell and stimulate
NHE1 activity through phosphorylation of S703 and 14-3-3 binding of NHE1. Accordingly,
palmitoylation of NHE1 might contribute to NHE1 being in a more active state in response
to serum. LPA acts as a mitogen, signaling through GPCRs to activate MAPK cascades.
While LPA signals through multiple pathways leading to the possibility that many factors
may be contributing to the increase in NHE1 palmitoylation here we show that LPA
coordinates NHE1 palmitoylation and phosphorylation to work in a cooperative manner
on NHE1. Phorbol esters such as PMA activate PKC signaling pathways, while no PKC
phosphorylation site has been established on NHE1, studies have found a defined role for
PMA activation of NHE1. A defined binding motif for phorbol esters on NHE1 shows PMA
acts in a PKC independent manner to activate NHE1 by increased association of the lipid
interacting domain (LID) on NHE1 with the membrane118. PMA increases NHE1
palmitoylation suggesting a potential role for palmitoylation facilitating LID membrane
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interaction through a PMA mediated mechanism. A potential NHE1 palmitoylation site is
located within the LID area at residue C561 supporting this theory. Insulin signaling occurs
through the PI3K/AKT phosphorylation pathway to phosphorylate NHE1 at S648. Insulin
decreases NHE1 palmitoylation indicating the AKT phosphorylation pathway stimulation
results in a reciprocal relationship between NHE1 phosphorylation and palmitoylation.
Taken together we show various stimuli that signal through different kinase
pathways contribute to NHE1 palmitoylation in both a cooperative and reciprocal
manner. This preliminary evidence points to palmitoylation as a possible connection point
linking different kinase pathways that phosphorylate NHE1. To continue exploring this
connection between NHE1 phosphorylation and palmitoylation we used specific kinase
inhibitors and measured the effect on NHE1 palmitoylation.
Looking at the insulin stimulated PI3K/AKT phosphorylation pathway we show
inhibition of PI3K and AKT results in increased NHE1 palmitoylation. AKT is responsible for
phosphorylation of NHE1 at S648, stimulation of this pathway using insulin increase NHE1
phosphorylation at S64870 and decreases NHE1 palmitoylation implying palmitoylation
and phosphorylation may work to regulate NHE1 in a reciprocal manner. The ERM protein
complex binds NHE1 between residues 550-566 which facilitates the formation of stress
fibers. Phosphorylation of S648 on NHE1 through AKT reduces actin stress fibers by
encouraging depolymerization. Inhibition of palmitoylation using 2BP results in decreased
formation of stress fibers and here we show treatment of cells with insulin which
promotes S648 phosphorylation leading to depolymerization of stress fibers decreases
NHE1 palmitoylation. The ERM binding domain is located between residues 550-566, and
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a potential palmitoylation site at residue C561 could offer an explanation for this
relationship. Palmitoylation of NHE1 decreases stress fiber formation which could be due
to the palmitate inhibiting ERM biding either sterically or by embedding the ERM binding
motif into the membrane thus preventing the formation of stress fibers.
Inhibition of MEK using PD98059 decreases NHE1 palmitoylation which aligns with
LPA increasing NHE1 palmitoylation. Phosphorylation of NHE1 S770/771 sites increase
NHE1 activity in response to sustained acidosis. This along with the fact that inhibition of
palmitoylation with 2BP results in a more acidic pHi provides preliminary evidence that
palmitoylation may play a role in cooperating with phosphorylation at these specific sites
to increase NHE1 activity. In conjunction with serum increasing NHE1 palmitoylation MEK
inhibition decreases NHE1 palmitoylation. Interestingly when Rsk, a step in the MEK
pathway and kinase that directly phosphorylates S703, is inhibited NHE1 palmitoylation
increases. Additionally, serum promotes phosphorylation of NHE1 at T653 through ROCK,
which when inhibited results in increased palmitoylation. While this seems contradictory,
it is likely due to the complexity of growth factor pathways influencing NHE1. Overall this
data provides preliminary evidence that palmitoylation and phosphorylation work to
create specific barcoding patterns that dictate a regulatory outcome and cellular response
involving NHE1.

Future Directions
Multiple studies are necessary to fully understand the effect of NHE1
palmitoylation on cellular processes and diseases related to NHE1. A major step forward
will be to determine the specific sites where NHE1 is palmitoylated. Once palmitoylation
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sites are known multiple studies can be done to understand the role of NHE1 specific
palmitoylation in NHE1 transport kinetics, localization, protein interactions, and cell
physiology

associated

with

NHE1.

Identification

of

the

palmitoylating

and

depalmitoylating enzymes involved in NHE1 palmitoylation would also provide targets to
regulate and study NHE1 function in a manner similar to kinases and phosphatases.
Additional work is necessary to understand how phosphorylation and
palmitoylation work in a coordinated manner to regulate NHE1. These studies will focus
on using mutations of the palmitoylation sites and phosphorylation sites to measure the
effect on the opposite modification. However, this would be time consuming considering
the sheer number of phosphorylation sites and potential palmitoylation sites and the
inherent issues with mutagenesis having potential off-site effects. Mass spectrometry will
be a useful tool to take a snapshot the effect of various stimuli on NHE1 palmitoylation
and phosphorylation at the same time without the complications that can accompany
mutagenesis.
NHE1 acts as a protein scaffold by interacting with various binding partners
including PIP2, ERM, and CHP1 and 2. NHE1 palmitoylation may alter these interactions,
especially considering two potential palmitoylation sites are located in the PIP2 and ERM
binding domains. Gaining a better understanding of the role palmitoylation plays in
regulating these binding partners would provide valuable information on how
palmitoylation is involved in protein scaffolding and on a larger scale cellular homeostasis
and dysfunction.
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By pursuing any one of these paths the knowledge gained will have far-reaching
impacts on our understanding of cellular homeostasis and on the multiple diseases where
NHE1 and palmitoylation are known to play significant roles such as cancer, Alzheimer
disease, diabetes, epilepsy, and general neurodegeneration.

Summary Conclusions
Overall, we found NHE1 is palmitoylated and that palmitoylation plays a role in
regulation of multiple vital cellular processes associated with the NHE1. Additionally, we
gathered preliminary data showing NHE1 palmitoylation and phosphorylation
physiological states as well as how NHE1 dysregulation contributes to multiple diseases.
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